US5292362A - Tissue bonding and sealing composition and method of using the same - Google Patents
Tissue bonding and sealing composition and method of using the same Download PDFInfo
- Publication number
- US5292362A US5292362A US07/727,607 US72760791A US5292362A US 5292362 A US5292362 A US 5292362A US 72760791 A US72760791 A US 72760791A US 5292362 A US5292362 A US 5292362A
- Authority
- US
- United States
- Prior art keywords
- composition
- component
- weight
- amount
- tissue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/00491—Surgical glue applicators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/001—Use of materials characterised by their function or physical properties
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
- A61L24/043—Mixtures of macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/28—Materials for coating prostheses
- A61L27/34—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B18/18—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves
- A61B18/20—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves using laser
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/00491—Surgical glue applicators
- A61B2017/00495—Surgical glue applicators for two-component glue
Definitions
- the present invention is directed to a composition adapted to bond separated tissues together or to coat tissues or prosthetic materials to enhance strength and water tightness preferably upon the application of energy and particularly to a composition which is activated by a laser to form a strong, biologically compatible bond or coating.
- Suturing suffers from several other drawbacks which have complicated surgical procedures.
- leaks often develop at the ends of the joined tissues which can require resuturing.
- suturing itself is a trauma to the tissue which can cause additional damage and extend the healing period. Further there are occurrences of inflammation in vicinity of the sutures which can result in late failure of a repair or anastomosis.
- tissue adhesive typically containing a concentrate of fibrinogen and thrombin as disclosed in U.S. Pat. Nos. 4,362,567, 4,414,976 and 4,909,251 and Canadian Patent No. 1,168,982.
- the adhesives require mixing immediately prior to application and react in a manner similar to the last stages of the clotting cascade to form a fibrin clot.
- the clot effects hemostasis, a cessation of bleeding.
- a small amount of tensile strength is present in the clot.
- Fibrin glue has been used in a variety of surgical procedures for its hemostatic properties, biocompatibility and as a modest reinforcement of the strength or more commonly the watertightness of a repair.
- Dennis F. Thompson et al. "Fibrin Glue: A Review of its Preparation, Efficacy and Adverse Effects as a Topical Hemostat", Drug Intell. Clin. Pharm. vol. 22, pp. 946-952 (1988); and Richard L. Burleson et al., "Fibrin Adherence to Biological Tissues", J. Surg. Res. vol. 25, pp. 523-539 ( 1978).
- Fibrin adhesive has significant drawbacks which has prevented its commercial use in the United States.
- fibrin glue preparations suffer from poor tensile strength.
- fibrin glue requires time consuming mixing of multiple reagents immediately prior to application.
- the glue polymerizes, and its removal disrupts the tissue on which it has been applied.
- Non-biological materials have been tried as surgical adhesives in an effort to reduce the risk of infection over adhesives obtained from pooled blood.
- Isobutyl-2-cyanoacrylate has been applied to separated tissues and has formed a solid watertight seal shortly after contact with the tissue.
- Khalid J. Awan et al. "Use of Isobutyl-2- Cyanoacrylate Tissue Adhesive in the Repair of Conjunctional Fistula in Filtering Procedures for Glaucoma", Annals of Ophth. pp. 851-853 (August, 1974).
- such adhesives have been criticized because they are irritating to tissues and difficult to apply.
- Andrew Henrick et al. "Organic Tissue Glue in the Closure of Cataract Incisions", J. CATARACT REFRACT. SURG. vol. 13, pp. 551-553 (September, 1987).
- Tissue welding involves the bonding of tissues together using an energy source such as a laser beam.
- a laser beam Several types of lasers have been found useful for tissue welding including Nd:YAG, CO 2 , THC:YAG and Argon.
- Nd:YAG, CO 2 , THC:YAG and Argon Several types of lasers have been found useful for tissue welding including Nd:YAG, CO 2 , THC:YAG and Argon.
- Tissue welding has been performed on a variety of tissues.
- a carbon dioxide laser has been used in nerve tissue repair as described in Julian E. Bailes et al., Microsurgery.
- Tissue welding has successfully repaired intestinal tissue.
- Semion Rochkind et al. "Low-Energy CO 2 Laser Intestinal Anastomosis: An Experimental Study” Lasers in Surgery and Medicine vol. 8 pp. 579-583 (1988).
- laser adhesives still suffer from deficiencies which make their universal application problematical.
- laser adhesives are difficult to apply to separated tissues. They are either in the form of semi-solids (e.g. fibrinogen) or liquid (e.g. albumin or blood).
- semi-solids e.g. fibrinogen
- liquid e.g. albumin or blood
- the product must be cut into strips and placed at the weld site. Quite often the solid strip will move during application requiring time consuming repositioning. Additionally, the strip may shrink when exposed to the laser beam and weld only a portion of the tissue. The unwelded portion may be large enough to permit the passage of blood. This requires the use of additional strips of welding material and time consuming repeat operations.
- Liquid laser adhesives are disadvantageous because they can run off of the weld site and thus may also require repeat applications.
- conventional laser adhesives made of protein materials, such as fibrinogen often form rigid welds which reduce the flexibility of the welded tissues, particularly welded blood vessels. If the vessel is subjected to normal pressure fluctuations which occur during the cardiac cycle, such as the unclamping of the blood vessel or when the patient moves suddenly, the weld can rupture causing internal bleeding and related complications.
- the present invention is directed to a composition suitable for bonding separated tissues and/or prosthetic materials together or for coating tissues or prosthetic materials, while maintaining sufficient flexibility to allow normal tissue or prosthetic function.
- the bonding or sealing of the separated tissues and/or prosthetic material can be enhanced by the application of energy and/or photons such as in the form of a laser beam.
- the composition may also be used to coat prosthetic materials to form a watertight or resistant seal.
- the viscosity of the composition can be varied so that delivery, positioning, and stability during welding and final elasticity and strength are appropriate for the selected application. Such attributes allow faster, more efficient surgical repair of damaged or weakened tissues than is possible with suturing or known sutureless procedures.
- the composition preferably in the form of a solution, most preferably an aqueous solution comprises a first component which provides the tensile strength necessary to keep the welded tissue together, joining the separated tissue or providing a watertight, flexible seal on a tissue or prosthetic or implant surface.
- the second component forming part of the composition is adapted to support the first component producing an improved degree of inter-relationship among the molecules of the first component. By combining the components in this way bond strength is enhanced, making this composition a significant improvement over the prior art.
- the second component may also contribute sufficient elasticity to enable the weld to move in unison with the tissue or vessel during its normal bodily functions.
- the second component may also function as a viscosity modifier according to the end use of the composition by raising or lowering the viscosity.
- a viscosity modifier and/or bonding enhancer may be added to the composition according to need.
- the resulting composition provides a tissue adhesive having excellent strength and superior handling characteristics.
- the composition is particularly suited for laser welding by forming a strong, uniform, elastic weld or coating.
- the first component is selected from natural or synthetic peptides enzymatically modified, cleaved, or shortened variants thereof and cross-linked derivatives thereof and mixtures thereof. Included among the peptides are simple proteins, conjugated proteins, and mixtures thereof. Examples of such proteins include globular proteins and fibrous or structural proteins, and mixtures thereof.
- globular proteins include synthetic or natural serum proteins, natural or synthetic derivatives thereof, salts, enzymatically, chemically, or otherwise modified, cleaved, shortened or cross-linked, oxidized or hydrolyzed derivatives or subunits thereof, and mixtures thereof.
- fibrous or structural proteins include synthetic or natural collagen, elastin, keratin, fibroin, fibrin, and fibronectin, natural or synthetic derivatives thereof, salts, enzymatically, chemically or otherwise modified, cleaved, shortened or cross-linked, oxidized or hydrolyzed derivatives or subunits thereof, and mixtures thereof.
- serum proteins examples include albumin, ⁇ -globulins, ⁇ -globulins, ⁇ -globulins, transthyretin, fibrinogen, and thrombin.
- Other globular and fibrous proteins as would be obvious to one skilled in the art may also be used.
- the second component is generally selected from compounds which support the first component such as by forming a matrix or gel or sol with the first component.
- These compounds are generally selected from natural or synthetic proteoglycans, glycoproteins, saccharides, polyalcohols, protein gels, gelatins, natural or synthetic derivatives thereof, enzymatically, chemically or otherwise modified, cleaved or shortened variants, salts, cross-linked, oxidized or hydrolyzed derivatives or subunits thereof of all of the above, and mixtures thereof.
- the proteoglycans are preferably natural or synthetic non-cellular body matrix materials found in the interstices between cells. Such materials are typically glycosaminoglycans and include hyaluronic acid, salts of hyaluronic acid including sodium hyaluronate, chondroitin sulfate, dermatan sulfate, keratan sulfate, heparin, and heparan sulfate.
- the saccharides are preferably selected from oligosaccharides such as fructose, and polysaccharides such as cellulose compounds, dextrans agarose, alginic acid and pectins.
- cellulose compounds examples include hydroxypropylmethylcellulose, hydroxycellulose, methylcellulose, carboxymethylcellulose, and hydroxyethylcellulose.
- the polyalcohols are preferably selected from glycerin, mannitol, sorbitol, polyvinyl alcohol, and polyethylene glycol.
- Other second component materials from these classes of compounds as would be obvious to one skilled in the art may also be employed.
- the composition is prepared in a form ranging from a flowable liquid to a sol to a viscous gel depending upon the application and the concentration of components.
- the composition is preferably employed in the form of a viscous gel for bonding of separated tissues.
- the formation of a watertight or resistant seal on tissues or prosthetic materials is most efficiently accomplished using a less viscous composition.
- the combination of the peptide and support material will spontaneously form a weld.
- it may be necessary to activate the composition with energy and/or photons.
- activation with energy and/or photons rapidly accelerates the bonding process.
- the energy and/or photons employed in the present invention must be capable of activating the composition in a manner which produces the desired bonding or coating characteristics.
- the composition can be activated through the application of energy and/or photons.
- the energy preferably has a wavelength in the electromagnetic spectrum, and is selected from X-rays, ultraviolet light, visible light, infrared light, and radiowaves.
- Thermal energy delivered through direct contact as for example with a probe heated electrically such as an electrocautery, or a probe heated through gas compression in the tip, or the passage of heated gas or liquid through the tip, may be used. Sound energy in the ultrasonic frequency, or radiowaves in the microwave range may be employed.
- the energy can be delivered in a continuous or noncontinuous fashion, in a narrow or broad band of electromagnetic wavelengths.
- Examples of photon sources include monochromatic and polychromatic light, coherent or noncoherent light, delivered in a continuous or noncontinuous fashion.
- noncontinuous energy and/or photon delivery include single and/or multiple pulse train delivery. Photons can be delivered in a polarized or nonpolarized fashion, direct or reflected, with or without internal or external interference.
- lasers including, but not limited to, those in the ultraviolet, visible, or infrared range.
- the THC:YAG (2150 ⁇ m), Nd:YAG (1064, 1320 nm), KTP (532 ⁇ m), Dye (577, 590, 610 nm), Krypton (647 nm), Argon (488 and 514 nm), Carbon dioxide (10,600 nm), Diode (810 nm), Excimer (193, 222, 249, 308, 351 nm) lasers are preferred.
- composition of the present invention can additionally contain viscosity modifiers and/or bonding enhancers in accordance with the end use of the composition.
- viscosity modifiers provides a composition with a viscosity particularly suited to tissues which are to be repaired or sealed.
- a composition having a high viscosity is preferably employed to bond separated tissues while lower viscosity compositions are best suited to form a coating for watertight sealing of continuous tissue masses and prosthetic materials such as GortexTM vascular grafts and the like.
- Such viscosity modifiers include compounds previously mentioned which are non-cellular body matrix materials such as hyaluronic acid and salts thereof such as sodium hyaluronate, or sodium chondroitin, or saccharides such as fructose, hydroxypropylmethylcellulose, hydroxyethylcellulose, carboxymethylcellulose, hydroxymethylcellulose, dextrans, agarose, alginic acid or pectins, or polyalcohols such as glycerine, or protein gels such as collagen, and caseinates, and mixtures thereof.
- non-cellular body matrix materials such as hyaluronic acid and salts thereof such as sodium hyaluronate, or sodium chondroitin, or saccharides such as fructose, hydroxypropylmethylcellulose, hydroxyethylcellulose, carboxymethylcellulose, hydroxymethylcellulose, dextrans, agarose, alginic acid or pectins, or polyalcohols such as glycerine, or protein gels such
- Bonding enhancers may also be used to improve the bonding strength of the composition.
- Certain second component materials may be selected for this purpose, and/or bond enhancers may be added to the composition as a third component.
- These are generally selected from polar compounds such as charged glycosaminoglycans, oligosaccharides and polysaccharides, polyalcohols, and polar dyes. Examples of these polar compounds include hyaluronic acid, chondroitin sulfate, carboxymethylcellulose, hydroxymethylcellulose, glycerine, indocyanine green, and fluorescein sodium.
- Polyvalent cations such as calcium, may also serve this purpose by binding to the negatively charged moieties in the proteins, such as albumin, and the glycosaminoglycans such as hyaluronic acid and chondroitin sulfate.
- mucoadhesives as second component materials and/or as a third component bond enhancer, is advantageous on mucin containing surfaces, such as the gastrointestinal tract, and the pulmonary system.
- mucoadhesives include carboxymethylcellulose and sodium alginate.
- Use of these materials on other surfaces, such as those with a high collagen content, which have a large concentration of hydroxyl groups, such as that imparted to the collagen through 4-hydroxyproline, may also be advantageous in facilitating bond formation.
- mucoadhesive molecules tend to attach to mucin through the entanglement of the polymer chains with mucin on the surface of the tissue, and unionized carboxylic acid groups and hydroxyl groups on the polymer may form hydrogen bonds to the mucin or other molecules on the collagen. It is believed that a high charge density is preferred for both swelling and hydrogen bonding for firm attachment to occur. (See J. R. Robinson et al.: Bioadhesive Polymers for Controlled Drug Delivery. Ann. NY Acad. Sci. 507:307-314, 1987, incorporated herein by reference.) Use of these materials as part of the present invention, therefore should be advantageous to facilitate the bonding of the composition to the desired tissue surface. Other mucoadhesives as would be obvious to one skilled in the art may also be employed.
- composition may additionally contain as needed pH modifiers, surfactants, antioxidants, osmotic agents, and preservatives.
- the components of the composition are combined together in quantities which provide a desired bonding strength as well as a viscosity which is particularly adapted to the end use.
- the amount of the peptide is in the range of from about 1 to 70% by weight, preferably about 8 to 35% by weight.
- the amount of support material varies depending on the support material chosen. Saccharides are typically employed in the range of from about 0.1 to 70% by weight.
- the amount of the glycosaminoglycans is preferably from about 0.1 to 20% by weight.
- Polyalcohols may be employed in an amount of from about 0.1 to 90% by weight.
- Protein gels and gelatins may be employed as second component materials in an amount of from about 5 to 80% by weight.
- the amount of additives such as viscosity modifiers and bonding enhancers is generally no more than about 65% by weight.
- the viscosity of the composition is chosen in accordance with the particular surgical procedure being performed.
- a viscosity of from about 1,000 to 1,000,000 centipoise is advantageously employed, preferably in the range of from about 20,000 to 200,000 centipoise.
- a composition having a viscosity in the preferred range can be easily placed on the separated tissues by ejecting through a hypodermic syringe and spread out by moving the syringe tip. In this viscosity range, the composition does not run off the tissues and remains fixed even when energy is applied to form the tissue weld.
- the composition preferably has a lower viscosity for applications requiring the formation of a watertight coating for sealing tissues or prosthetic materials.
- the preferred viscosity for coating is in the range of from 10 to 1,000 centipoise.
- the lower viscosity is preferred because the composition should be readily spreadable to efficiently cover the tissue or material to be coated.
- the viscosity of the composition decreases with increasing shear forces. Accordingly, the viscosity of the composition can be modulated by altering the shear forces present when the composition is applied to the surface.
- a composition which is very thick when it is stationary can be injected through a graft at a rapid or high sheer rate to reduce its viscosity during the transit phase in which the graft is coated with the material.
- psuedoplasticity is also characteristic of blood. It is ideal for welding at sites that are not subject to shearing forces during the welding process. When the composition is being injected, shear forces are high, and the viscosity decreases. This allows for easy injection. After being deposited on the tissue, the shear forces drop to zero, and the viscosity of the composition increases correspondingly. As a result, the composition stays localized on the tissue in the area to be welded.
- the composition of the present invention provides a tissue bond having high tensile strength, elasticity, deformability, water tightness, viscosity and adhesivity for a large variety of surgical procedures.
- the composition can also be used to coat implantable devices to enhance their strength and resistance to fluids, to seal pores in the weave of the material, and reduce thrombogenicity.
- the composition is easily reproducible, non-infectious and stays stable and therefore can be used with greater speed and reliability than known surgical adhesives.
- composition of the present invention can be used to bond separated tissues together and to coat continuous tissue masses or prosthetic materials to enhance their strength and/or make them impermeable to fluids.
- the coating applications of the invention make it possible to reinforce a weakened tissue such as an arterial wall.
- the preferred proteins used in the present invention are structural proteins such as collagen and serum proteins such as albumin. Although fibrinogen and fibrin are not presently preferred embodiments due to the risk of infection and stability problems, should these problems be overcome by new production and/or purification techniques, fibrinogen and fibrin would become preferred embodiments of the present invention particularly in combination with albumin.
- Collagen is the most abundant protein in the body. There are five types of collagen, each containing three polypeptides of about 1,000 residues per chain. The main function of collagen is to maintain the shape and to resist the deformation of the tissues. In a similar fashion, the ropelike collagen fibrils help to enhance bond strength and to resist deformation in the tissue bonding or sealing composition of the present invention.
- collagen when collagen is heated it can be denatured, and solubilized for easy application as a gelatin-like solution. When cooled, the collagen is partially renatured, resulting in a gel formation with excellent tensile strength. Heated collagen, therefore, is an ideal protein component in the present tissue bonding or sealing composition. Through heating, collagen can be solubilized and easily injected or applied, and by cooling it can be turned into a gel which provides both tensile strength and flexibility to the bond. Collagen can also be rendered in a sterile form. Moreover, collagen is more stable than its fibrin counterpart, both on the shelf and in vitro and collagen does not expose the recipient to the risk of infection as does fibrin glue.
- Albumin when used in the present composition, provides distinct advantages over current procedures using "biological glues" which employ fibrin obtained from pooled blood samples. This exposes the recipient to the risk of infections from AIDS, Hepatitis A, Hepatitis non A and non B, Cytomegalovirus, Jakob-Creutzfeld disease, and others.
- the present composition containing human albumin on the other hand, while obtained from pooled blood products, does not expose the patient to these risks.
- Human albumin unlike human fibrin, can be subjected to ultrafiltration techniques which results in a high yield of albumin free of infectious agents. Moreover, human albumin is more stable than its fibrin counterpart, both on the shelf and in vivo.
- fibrin can be activated by thrombin and calcium, which are both present in the blood and other body tissues. Moreover, after its use, plasma fibrinolytic activity immediately begins to degrade the fibrin glue. As there is no enzyme system specifically designed to degrade albumin, its absorption will be slower than that of the fibrin glue counterpart. On the shelf, albumin is also more stable than fibrin glue.
- Albumin is a transport protein with a molecular weight of 66,500 Daltons, and a half life of 15-20 days. It accounts for 70-80% of the colloid osmotic pressure of the plasma, and is distributed throughout the extracellular water. More than 60% of human albumin is located in the extravascular fluid compartments. It is, therefore, ideally suited for welding as it is present in most of the tissues which are to be welded, and will not cause a tissue inflammatory response. Moreover, its half-life exceeds the time period necessary for wound strength to reach a level sufficient to resist normal stresses.
- the preferred polysaccharides have a high molecular weight and form long chain molecules which produce viscous, gel-like materials at low concentrations. Additionally, the presence of multiple charged or uncharged side chains may be advantageous to facilitate gel formation, production of a high viscosity composition, and/or interaction between molecules in the composition and/or tissue. Low molecular weight, small chain polysaccharides require higher concentrations to produce viscous, gel-like materials, and tend to be less desirable.
- One of the preferred polysaccharides is hydroxypropylmethylcellulose which is preferably used in a sterile aqueous solution.
- a sterile solution it may be formulated to have a molecular weight exceeding 80,000 daltons and a viscosity of at least about 4,000 centipoise. See, for example, Thomas J. Liesegang et al., "The Use of Hydroxypropyl Methyl Cellulose in Extracapsular Cataract Extraction with Intraocular Lens Implantation", Am. J. Ophth. vol. 102, pp 723-726 (December, 1986).
- Another preferred polysaccharide is carboxymethylcellulose, which is also preferably used in a sterile aqueous solution.
- a sterile solution it may be formulated in a 1% aqueous solution to have a viscosity of 10-3,000 centipoise or higher depending on its molecular weight.
- a 2% aqueous solution of 45,000 Dalton's has a viscosity of 10-20 centipoise
- a 2% solution of 100,000 Dalton's has a viscosity of 400-800 centipoise
- a 1% aqueous solution of 200,000 Dalton's has a viscosity of 1500-3000 centipoise.
- alginic acid is also preferably use in a sterile aqueous solution.
- a sterile solution it can be formulated into a 2% solution having a viscosity of 250 to 14,000 centipoise or higher, depending on its molecular weight.
- a 2% solution of alginic acid weighing 200,000 Dalton's has a viscosity of 14,000 centipoise
- a 2% solution of alginic acid weighing 150,000 Dalton's has a viscosity of 3,500
- a 2% solution of alginic acid weighing 100,000 Dalton's has a viscosity of 250 centipoise.
- Pectin is another preferred saccharide, which can be formulated into an aqueous solution.
- glycosaminoglycans which include hyaluronic acid and salts thereof, particularly sodium hyaluronate and chondroitin sulfate, are preferred.
- Hyaluronic acid is a polymer centered in the extracellular matrix of animals and humans. It is thought to form the filamentous backbone of both cartilage and other connective tissues.
- Hyaluronic acid has a molecular weight of 4 to 80 ⁇ 10 6 Daltons.
- hyaluronic acid is characterized by repeating disaccharide subunits of sodium glucuronate linked to an N-acetylglucosamine molecule by a ⁇ 1 ⁇ 3 glucosidic bond. The disaccharide units are linked together with ⁇ 1 ⁇ 4 glucosidic bond to form large polymers. Each subunit has one negative charge, which may help to explain its bond strength enhancing affect. (See Principles of Biochemistry: Mammalian Biochemistry, 7th edition, edited by Emil Smith et al., pp. 7 and 229 (1983).
- Hyaluronic acid and its salts have other advantages.
- sodium hyaluronate has a viscosity of 40,000 centipoise at a shear rate of 2 sec. -1 at 25° C., and over 200,000 centipoise at a shear rate of zero.
- This non-Newtonian, or pseudoplastic viscous property of hyaluronic acid makes it ideal for tissue welding.
- the viscosity of hyaluronic acid is low, facilitating injection. This allows for its easy application to tissues.
- low shear rates such as after application to tissues, its viscosity is high.
- hyaluronic acid is ideally suited for tissue welding for two reasons. First, it helps to increase the tissue adhesive strength by providing a backbone for the protein component of the tissue adhesive material. Second, the pseudoplastic properties of hyaluronic acid provide it with ideal handling characteristics.
- Chondroitin sulfate is a polymer centered in the extracellular matrix of animals and humans. It has a molecular weight of 22,500 daltons, and is composed of a repeating disaccharide subunit of glucuronic acid in ⁇ 1 ⁇ 3 linkage with N-Acetylgalactosamine. The subunits are then combined by ⁇ 1 ⁇ 4 linkage to form large polymers. Unlike hyaluronic acid, chondroitin sulfate contains a double negative charge per repeating disaccharide unit, which may enhance bond strength in certain instances. This may help in the bonding and sealing of corneal tissue, which has the highest natural concentration of chondroitin sulfate of any tissue in the body.
- Chondroitin sulfate like hyaluronic acid, is highly viscous in concentrations of 50 mg/ml, where its viscosity is 4000 centipoise (at shear rate of 2 sec -1 , 25° C.). However, unlike hyaluronic acid, chondroitin sulfate is a Newtonian fluid, and does not change viscosity with changing shear rates. This property will allow it to remain localized more readily in areas where there are large shear forces during bonding.
- the use of long chain molecules, particularly saccharides, and proteoglycans is advantageous.
- concentration of these molecules, or their molecular weight at a fixed concentration is increased, higher viscosity and gel-like materials tend to be produced.
- concentration of these molecules, or their molecular weight at a fixed concentration is decreased, lower viscosity, more watery materials tend to be produced. Therefore, through modification of the long chain molecule's molecular weight and/or concentration, the handling characteristics of the composition can be controlled to suit the desired application.
- compositions in which thicker, more viscous handling characteristics are desirable can be formulated by increasing the molecular weight and/or concentration of the second component.
- compositions in which a thin, liquid, watery formulation is desirable can be formulated by decreasing the molecular weight and/or concentration of the second component.
- composition of the present invention may also include indogenous or exogenous chromophores to facilitate visualization of the material during placement into warm blooded animals.
- a chromophore will allow material which becomes displaced from the desired application site to be easily visualized, and subsequently removed using a cellulose sponge, gauze pad, or other absorbing material.
- endogenous chromophores such as hemoglobin
- Krueger R, Almquist E Argon laser coagulation of blood for anastomosis of small vessels. Lasers Surg. Med. 5:55-60, January, 1985.
- exogenous chromophores for aid in the placement of biological glues has been previously described (see I. Nasaduke, et al.
- Chromophores that may be used, include, but are not limited to fluorescein isothiocyanate, indocyanine green, silver compounds such as silver nitrate, rose bengal, nile blue and Evans Blue, Q-SwitchTM, a dye made by Kodak, Inc., Sudan III, Sudan Black B and India Ink.
- the chromophores are preferably present in a concentration of from about 0.01 to 50% by weight based on the total weight of the composition. Other chromophores as would be obvious to one skilled in the art may also be employed.
- the present invention may also include substances which alter absorption characteristics of the composition so that the composition absorbs energy at low energy levels. This enables the heating of the material using certain wavelengths of the electromagnetic spectrum which are selectively absorbed by the energy absorbing compound. For example, this would allow heating of the material using certain lasers whose energy would otherwise not be absorbed by the composition of the present invention, and allows the composition to be welded to the target using these lasers. These substances reduce possible collateral damage to adjacent tissues typically associated with high energy level activators such as laser beams. See, "Mehmet C. Oz et al., "Tissue Soldering by Use of Indocyanine Green Dye-enhanced Fibrinogen with the Near Infrared Diode Laser", J. Vasc. Surg. vol. 11 no.
- Exogenous dyes such as indocyanine green, fluorescein and endogenous chromophores such as hemoglobin and melanin and the like are particularly suited for this purpose. These dyes also may increase adhesivity, weld strength and viscosity.
- the dyes are preferably present in the composition in an amount of from about 0.01 to 50% by weight based on the total weight of the composition.
- indocyanine green is a dye that selectively binds to human or animal albumin and has a maximum absorbance at 805 nm in an albumin solution.
- continuous wave diode laser light which is commercially available at 808 nm wavelength, can be selectively used to heat and coagulate the albumin.
- the selection of the peptide used as the first component is affected by the laser-dye combination desired. Peak absorption for indocyanine green in water solution is 770 nm. This does not match the output of the diode laser.
- the 805 nm peak is obtained in albumin solution but not in solution with other proteins, such as fibrinogen. This effect is observed independent of albumin absorption which is low at 805 nm.
- dye-laser combinations include, but are not limited to, fluorescein isothiocyanate (Absorbance 490 nm) and an argon laser operating at 488-514 nm; silver compounds such a silver nitrate and a krypton laser (676 nm); dye compounds such as rose bengal, nile blue and Evans blue and Dye lasers absorbing in the range of 200 to 610 nm.
- Q-switch IITM a dye obtained from Kodak, absorbs light from a Nd:YAG laser at 1064 nm and 1320 nm.
- Sudan III, Sudan black B and India Ink may also be utilized to selectively adsorb light from any of the above-mentioned lasers.
- compositions may additionally contain as needed pH modifiers, surfactants, antioxidants, osmotic agents, and preservatives.
- pH modifiers include acetic acid, boric acid, hydrochloric acid, sodium acetate, sodium bisulfate, sodium borate, sodium carbonate, sodium citrate, sodium hydroxide, sodium nitrate, sodium phosphate, sodium sulfite, and sulfuric acid.
- surfactants include benzalkonium chloride.
- antioxidants include bisulfates.
- osmotic agents include sodium chloride.
- preservatives examples include chlorobutanol, sorbate, benzalkonium chloride, thimerosal, methylparaben, propylparaben, Ethylenediaminetetraacetic acid (EDTA), and polyquad.
- pH modifiers typically the pH modifiers, surfactants, antioxidants, osmotic agents, and preservatives are present in a concentration of from about 0.001 to 5% by weight.
- the method of formulating the composition of the present invention may be performed in a number of ways, including, but not limited to the following preparation techniques, which generally result in a well formulated composition.
- the preparation is generally performed at 25°-30° C. or cooler for globular proteins, and may be performed at temperatures of from 25°-200° C. or higher, preferably 25°-100° C. for collagen, and other fibrous proteins.
- the first and second components are formulated into sterile aqueous solutions at the desired concentration.
- the first or second component is anhydrous, lyophilized, or partially hydrolyzed, they are hydrated to the desired concentration with sterile water or a sterile aqueous solution containing chromophores, electrolytes, pH modifiers, surfactants, antioxidants, osmotic agents, and preservatives.
- chromophores chromophores
- electrolytes chromophores
- pH modifiers chromophores
- surfactants antioxidants
- antioxidants antioxidants
- osmotic agents osmotic agents
- the first and second components are combined in a ratio which is determined by the desired end use of the composition.
- the material is mixed for 5 or more minutes, or until a homogenous solution, gel or sol is formed.
- the material may additionally be cooled to from 5°-20° C. to aid in sol or gel formation.
- additional material can be added to increase the viscosity of the material, the bond strength of the material, to enhance the visualization of the material.
- Other agents such as pH modifiers, surfactants, antioxidants, osmotic agents, and preservatives may be added at this time.
- the product of the third step is then packaged and stored in one of a number of ways.
- the materials can be placed in an aqueous form into a sterile syringe, or vial; and (2) the materials can be dehydrated, as for example through lyophilization, and stored in an anhydrous or partially hydrated state.
- dark, pigmented containers are preferred to prevent light activation or decay of the composition.
- refrigeration of the product at 4°-10° C. is generally preferred.
- Freshly enucleated porcine eyes were used to determine the strength of the bonding in closing corneoscleral cataract incisions similar to those used in cataract extraction surgery.
- a 64 beaver blade was used to make a 5-10 mm partial thickness scleral incision, 1-3 mm posterior to the limbus. The incision was extended anteriorly into clear cornea, and a superblade was used to enter the anterior chamber.
- a 25 G butterfly needle was inserted into the anterior chamber through clear cornea, and was attached to a water column of Dextrose 5% Normal Saline solution.
- the water column was elevated until leakage was noted at the wound margin. The process was repeated at least three times until reproducible-results were obtained. The glue was then applied and congealed with the laser to form a firm seal. The water column was then elevated until leakage could be visualized around the glue margin, which is reported as the bursting pressure. If the bursting pressure was near the baseline values, additional glue was applied to the area of leakage, and additional laser energy was applied. If this resulted in a strong bond, this value was reported as the bursting pressure.
- Example 2 The same composition was prepared as in Example 1 except that the indocyanine green dye was omitted. The sample was placed on tissue specimens and activated as described in Example 1. The results are shown in Table 2.
- composition of the present invention Seven samples of the composition of the present invention were prepared by combining sodium hyaluronate (HealonTM manufactured by Pharmacia Inc. and Amvisc PlusTM manufactured by Med Chem Products, Inc.) and a mixture of 25% human albumin which contained 10 mg/ml of indocyanine green dye. The mixtures were refrigerated overnight to allow for adequate mixing.
- sodium hyaluronate HealonTM manufactured by Pharmacia Inc. and Amvisc PlusTM manufactured by Med Chem Products, Inc.
- human albumin which contained 10 mg/ml of indocyanine green dye.
- the mixtures were applied to tissues in the same manner as described in Example 1 and exposed to laser light from a diode laser manufactured by Spectra-Physics, at a wavelength of 808 nm with an energy output of 300-450 milliwatts and a power density of 12 watts/cm 2 and a spot size of 2 mm.
- the glue On application of the laser energy an area of whitening occurred, followed by shrinkage, and then congealed. After adequate laser application, the glue set in a fashion similar to that seen with commercially available rubber cement.
- the elastic properties of the glue could be modulated by additional laser energy. As more energy was applied, firmer, less flexible, stronger bonds could be formed. At lower energy levels, the bond was more elastic. Over time, when allowed to dry further, both types of bonds appeared to become stronger. However, total drying results in a brittle, friable material and is undesirable.
- compositions of the present invention exhibited a mean tensile strength far exceeding the tensile strength of the protein (human fibrinogen or albumin) alone.
- a composition in accordance with the present invention was tested on three patients in accordance with the following.
- the patient population comprised end-stage renal disease patients requiring arteriovenus fistula for vascular access for hemodialysis. Consent for experimental treatment was obtained under an approved Institutional Review Board protocol. Using standard techniques the radial artery and a suitable forearm vein were isolated. 6-7 mm anastomoses were created between the artery and vein using a loop of 6 mm GortexTM graft (standard wall).
- the glue was sealed to the edge of the anastomosis and suture holes using a KTP laser (532 nm, 1 mm spot size, 500 mW).
Abstract
Description
TABLE 1 ______________________________________ Hyaluronic Acid 10 mg/ml 0.55 ml 25% Human Albumin 0.55 ml Indocyanine green dye 5.5 mg Incision Length 9 mm Distance from limbus 2 mm Normal Pre-Glue Bursting pressure 4 in. H.sub.2 O Post-Welding Bursting pressure 60 in. H.sub.2 O Viscosity 7 ______________________________________
TABLE 2 ______________________________________ Hyaluronic Acid 10 mg/ml 0.75 ml 25% Human Albumin 0.75 ml Incision Length 9 mm Distance from limbus 2 mm Normal Pre-Glue Bursting pressure 4 in. H.sub.2 O Post Welding Bursting pressure >60 in. H.sub.2 O Viscosity 7 ______________________________________
TABLE 3 __________________________________________________________________________ 25% HUMAN ALBUMIN WITH DISTANCE NORMAL PRE- POST-WELDING 10 MG/ML OF INCISION FROM GLUE BURSTING BURSTING HEALON ICG DYE LENGTH LIMBUS PRESSURE PRESSURE SAMPLE (PARTS) (PARTS) (MM) (MM) (INCHES H.sub.2 O) (INCHES H.sub.2 O) VISCOSITY __________________________________________________________________________ 3 10 1 9 2 2 4 10 4 5 1 8 2 2 16 10 5 2 1 9 2 4 52 8 6 1 1 10 2 2 40 7 7 1 2 10 2 2 10 6 8 1 5 9 2 6 30 2 9 1 10 9 2.5 4 10 1 __________________________________________________________________________
TABLE 4 ______________________________________ AmviscPlus ™ 1 part 25% Human Albumin 1 part Incision Length 6 mm Distance from limbus 2.5 mm Normal Pre-Glue Bursting pressure 4 in. H.sub.2 O Post-Welding Bursting pressure 41 in. H.sub.2 O Viscosity 7 ______________________________________
TABLE 5 ______________________________________ Occucoat ™ 1 part Albumin 1 part Incision Length 7 mm Distance from limbus 2 mm Normal Pre-Glue Bursting pressure 8 in. H.sub.2 O Post-Welding Bursting pressure 32 in. H.sub.2 O Viscosity 2 ______________________________________
TABLE 6 __________________________________________________________________________ NORMAL POST- 25% HUMAN PRE-GLUE WELDING ALBUMIN DISTANCE BURSTING BURSTING WITH 10 INCISION FROM PRESSURE PRESSURE VISCOAT MG/ML OF LENGTH LIMBUS (INCHES INCHES SAMPLE (PARTS) ICG DYE (MM) (MM) H.sub.2 O) (H.sub.2 O) VISCOSITY __________________________________________________________________________ 12 1 1 7 3.0 6 13 8 __________________________________________________________________________ 25% HUMAN NORMAL POST- ALBUMIN PRE-GLUE WELDING WITH 10 DISTANCE BURSTING BURSTING MG/ML OF INCISION FROM PRESSURE PRESSURE HONEY ICG DYE LENGTH LIMBUS (INCHES INCHES SAMPLE (PARTS) (PARTS) (MM) (MM) H.sub.2 O) (H.sub.2 O) VISCOSITY __________________________________________________________________________ 13 1 1 7 3.0 4 20 3 __________________________________________________________________________ 25% HUMAN NORMAL POST- ALBUMIN PRE-GLUE WELDING 15% WITH 10 DISTANCE BURSTING BURSTING DEXTRAN MG/ML OF INCISION FROM PRESSURE PRESSURE SOLUTION ICG DYE LENGTH LIMBUS (INCHES INCHES SAMPLE (PARTS) (PARTS) (MM) (MM) H.sub.2 O) (H.sub.2 O) VISCOSITY __________________________________________________________________________ 14 1 1 10 2.5 4 40 3 __________________________________________________________________________
TABLE 7 ______________________________________ Glycerine 2 parts 25% Human Albumin with 10 mg/ml of ICG dye 1 part Incision Length 9 mm Distance from limbus 2 mm Normal Pre-Glue Bursting pressure 22 in. H.sub.2 O Post-Welding Bursting pressure 32 in. H.sub.2 O Viscosity 3 ______________________________________
TABLE 8 ______________________________________ MEAN TENSILE STRENGTH SAMPLE COMPOSITION (G/CM.sup.2) ______________________________________ CONTROL A) indocyanine green 0.5% <100 CONTROL B) none <100 CONTROL C) human fibrinogen 70% + 113 indocyanine green 0.5% CONTROL D) human albumin 25% + indocyanine 250 green 0.5% 16 human albumin 12% + sodium 441 hyaluronate 0.5% + indocyanine green 0.5% 17 human albumin 25% + dextran 386 15% + indocyanine green 0.5% 18 bovine collagen 13% + sodium 531 hyaluronate 0.3% + indocyanine green 0.5% 19 human albumin 8% + sodium 514 hyaluronate 0.7% 20 human albumin 25% + collagen 404 (bovine gelatin) 20% ______________________________________
TABLE 9 ______________________________________ Treatment Group Gortex ™ AVF with composition Mean Blood Loss Mean Bleeding Time 14.7 g 4 min Control Group Gortex AVF without composition Mean Blood Loss Mean Bleeding Time 24.0 g 4 min ______________________________________
Claims (42)
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/727,607 US5292362A (en) | 1990-07-27 | 1991-07-09 | Tissue bonding and sealing composition and method of using the same |
ES91915440T ES2137930T3 (en) | 1990-07-27 | 1991-07-23 | COMPOSITION TO JOIN AND SEAL FABRICS AND METHOD TO USE THE SAME. |
AT91915440T ATE183656T1 (en) | 1990-07-27 | 1991-07-23 | COMPOSITION FOR BONDING AND SEALING FABRIC AND METHOD FOR USE THEREOF |
AU84979/91A AU8497991A (en) | 1990-07-27 | 1991-07-23 | Tissue bonding and sealing composition and method of using the same |
DE69131556T DE69131556T2 (en) | 1990-07-27 | 1991-07-23 | COMPOSITION FOR CONNECTING AND SEALING TISSUES AND METHOD FOR THEIR USE |
EP91915440A EP0542880B1 (en) | 1990-07-27 | 1991-07-23 | Tissue bonding and sealing composition and method of using the same |
CA002087957A CA2087957C (en) | 1990-07-27 | 1991-07-23 | Tissue bonding and sealing composition and method of using the same |
PCT/US1991/005186 WO1992002238A1 (en) | 1990-07-27 | 1991-07-23 | Tissue bonding and sealing composition and method of using the same |
JP3514745A JPH06507376A (en) | 1990-07-27 | 1991-07-23 | Tissue joining and sealing compositions and methods of use thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/560,069 US5209776A (en) | 1990-07-27 | 1990-07-27 | Tissue bonding and sealing composition and method of using the same |
US07/727,607 US5292362A (en) | 1990-07-27 | 1991-07-09 | Tissue bonding and sealing composition and method of using the same |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US07/560,069 Continuation-In-Part US5209776A (en) | 1990-07-27 | 1990-07-27 | Tissue bonding and sealing composition and method of using the same |
Publications (1)
Publication Number | Publication Date |
---|---|
US5292362A true US5292362A (en) | 1994-03-08 |
Family
ID=27072241
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US07/727,607 Expired - Lifetime US5292362A (en) | 1990-07-27 | 1991-07-09 | Tissue bonding and sealing composition and method of using the same |
Country Status (9)
Country | Link |
---|---|
US (1) | US5292362A (en) |
EP (1) | EP0542880B1 (en) |
JP (1) | JPH06507376A (en) |
AT (1) | ATE183656T1 (en) |
AU (1) | AU8497991A (en) |
CA (1) | CA2087957C (en) |
DE (1) | DE69131556T2 (en) |
ES (1) | ES2137930T3 (en) |
WO (1) | WO1992002238A1 (en) |
Cited By (246)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5510102A (en) * | 1995-01-23 | 1996-04-23 | The Regents Of The University Of California | Plasma and polymer containing surgical hemostatic adhesives |
WO1996038093A2 (en) * | 1995-06-02 | 1996-12-05 | Children's Medical Center Corporation | Method for laser mediated tissue welding with enhanced strength |
WO1996041864A1 (en) * | 1995-06-13 | 1996-12-27 | The Regents Of The University Of California | Diode laser heated micro-reaction chamber with sample detection means |
US5612050A (en) * | 1993-03-23 | 1997-03-18 | Focal, Inc. | Apparatus and method for local application of polymeric material to tissue |
US5660873A (en) * | 1994-09-09 | 1997-08-26 | Bioseal, Limited Liability Corporaton | Coating intraluminal stents |
US5662712A (en) * | 1993-04-28 | 1997-09-02 | Focal, Inc. | Apparatus for intraluminal photothermoforming |
EP0792125A1 (en) * | 1994-11-15 | 1997-09-03 | Sisters Of Providence In Oregon | Elastin, and elastin-based biomaterials and process |
US5665063A (en) * | 1994-06-24 | 1997-09-09 | Focal, Inc. | Methods for application of intraluminal photopolymerized gels |
US5669934A (en) * | 1991-02-13 | 1997-09-23 | Fusion Medical Technologies, Inc. | Methods for joining tissue by applying radiofrequency energy to performed collagen films and sheets |
US5705203A (en) | 1994-02-07 | 1998-01-06 | E. Khashoggi Industries | Systems for molding articles which include a hinged starch-bound cellular matrix |
US5707331A (en) * | 1995-05-05 | 1998-01-13 | John R. Wells | Automatic multiple-decanting centrifuge |
US5716675A (en) | 1992-11-25 | 1998-02-10 | E. Khashoggi Industries | Methods for treating the surface of starch-based articles with glycerin |
EP0832095A1 (en) * | 1995-06-07 | 1998-04-01 | Cedars-Sinai Medical Center | A method of cross-linking amino acid-containing polymers using photoactivatable chemical cross-linkers |
US5758663A (en) * | 1992-04-10 | 1998-06-02 | Wilk; Peter J. | Coronary artery by-pass method |
US5776388A (en) | 1994-02-07 | 1998-07-07 | E. Khashoggi Industries, Llc | Methods for molding articles which include a hinged starch-bound cellular matrix |
US5779673A (en) * | 1995-06-26 | 1998-07-14 | Focal, Inc. | Devices and methods for application of intraluminal photopolymerized gels |
US5817303A (en) * | 1995-05-05 | 1998-10-06 | Protein Polymer Technologies, Inc. | Bonding together tissue with adhesive containing polyfunctional crosslinking agent and protein polymer |
US5824015A (en) * | 1991-02-13 | 1998-10-20 | Fusion Medical Technologies, Inc. | Method for welding biological tissue |
US5843544A (en) | 1994-02-07 | 1998-12-01 | E. Khashoggi Industries | Articles which include a hinged starch-bound cellular matrix |
US5849761A (en) * | 1995-09-12 | 1998-12-15 | Regents Of The University Of California | Peripherally active anti-hyperalgesic opiates |
US5869468A (en) * | 1994-04-04 | 1999-02-09 | Freeman; William R. | Treatment of conditions of abnormally increased intraocular pressure by administration of phosphonylmethoxyalkyl nucleoside analogs and related nucleoside analogs |
US5874537A (en) * | 1991-01-29 | 1999-02-23 | C. R. Bard, Inc. | Method for sealing tissues with collagen-based sealants |
WO1999034219A1 (en) * | 1997-12-24 | 1999-07-08 | Kalibrant Limited | A composition for use in fluorescence assay systems |
US5929044A (en) * | 1997-08-14 | 1999-07-27 | Cornell Research Foundation | Protein solder composition and method of use |
US5935094A (en) * | 1996-05-03 | 1999-08-10 | Uros Corporation And The Regents Of The University Of California | Pentosanpolysulfate coating for medical devices |
US5962477A (en) * | 1994-04-12 | 1999-10-05 | Adolor Corporation | Screening methods for cytokine inhibitors |
GB2336207A (en) * | 1997-12-24 | 1999-10-13 | Kalibrant Limited | A composition for use in fluorescence assay systems |
WO1999051282A1 (en) * | 1998-04-06 | 1999-10-14 | Cornell Research Foundation, Inc. | Composition for tissue welding and method of use |
EP0956869A2 (en) * | 1998-05-15 | 1999-11-17 | Hogy Medical Co., Ltd. | Tissue sealant |
US5994325A (en) * | 1991-05-31 | 1999-11-30 | Gliatech Inc. | Methods and compositions based on inhibition of cell invasion and fibrosis by anionic polymers |
US6074663A (en) * | 1995-01-16 | 2000-06-13 | Baxter International Inc. | Method of using cross-linked fibrin material |
US6083902A (en) * | 1994-05-02 | 2000-07-04 | Bristol-Myers Squibb Company | Recombinant fibrin chains, fibrin and fibrin-homologs |
US6087552A (en) * | 1994-11-15 | 2000-07-11 | Sisters Of Providence Of Oregon | Method of producing fused biomaterials and tissue |
WO2000040277A1 (en) * | 1999-01-08 | 2000-07-13 | Browdie David A | Tissue adhesive for treating vigorously bleeding surfaces |
EP1018983A1 (en) * | 1997-02-07 | 2000-07-19 | Sisters Of Providence In Oregon | Method of producing biomaterials |
US6113636A (en) * | 1997-11-20 | 2000-09-05 | St. Jude Medical, Inc. | Medical article with adhered antimicrobial metal |
US6129928A (en) * | 1997-09-05 | 2000-10-10 | Icet, Inc. | Biomimetic calcium phosphate implant coatings and methods for making the same |
WO2000062827A2 (en) * | 1999-04-16 | 2000-10-26 | Cohesion Technologies, Inc. | Rapid gelling biocompatible polymer composition |
US6183498B1 (en) | 1999-09-20 | 2001-02-06 | Devore Dale P. | Methods and products for sealing a fluid leak in a tissue |
US6190691B1 (en) | 1994-04-12 | 2001-02-20 | Adolor Corporation | Methods for treating inflammatory conditions |
EP1082126A1 (en) * | 1998-05-27 | 2001-03-14 | Hadasit Medical Research Services & Development Co. Ltd. | Novel peptides |
WO2001017571A1 (en) * | 1999-09-03 | 2001-03-15 | Sulzer Vascutek Limited | Sealant for vascular prostheses |
US6211335B1 (en) * | 1995-01-20 | 2001-04-03 | The Microsearch Foundation Of Australia | Method of tissue repair |
WO2001026624A1 (en) * | 1999-10-08 | 2001-04-19 | Providence Health System - Oregon | Biocompatible albumin lamina and method |
WO2001030405A1 (en) * | 1999-10-28 | 2001-05-03 | Tissuemed Ltd. | Flexible sheets for use in therapy |
US6239190B1 (en) * | 1995-01-27 | 2001-05-29 | Tissuemed Limited | Enhancement of activation for ‘biological’ tissue adhesives, bonding agents and sealants using “color change” chromophores |
US6258872B1 (en) * | 1997-06-20 | 2001-07-10 | Protein Polymer Technologies, Inc. | Methods of using primer molecules for enhancing the mechanical performance of tissue adhesives and sealants |
WO2001058452A1 (en) * | 2000-02-08 | 2001-08-16 | Tissuemed Limited | Thermal ablation of tissue |
DE10015145A1 (en) * | 2000-03-29 | 2001-10-11 | Fraunhofer Ges Forschung | Connector for vessel anastomosis comprises mesh metal inner sleeve covered by biocompatible biodegradable polymer outer sleeve to clamp vessel ends after laser shrinkage with retained flow section. |
US6310036B1 (en) * | 1999-01-09 | 2001-10-30 | Last Chance Tissue Adhesives Corporation | High strength, Bio-compatible tissue adhesive and methods for treating vigorously bleeding surfaces |
US6348679B1 (en) | 1998-03-17 | 2002-02-19 | Ameritherm, Inc. | RF active compositions for use in adhesion, bonding and coating |
US6351663B1 (en) | 1999-09-10 | 2002-02-26 | Akorn, Inc. | Methods for diagnosing and treating conditions associated with abnormal vasculature using fluorescent dye angiography and dye-enhanced photocoagulation |
WO2002024159A2 (en) | 2000-09-22 | 2002-03-28 | Durect Corporation | Implantable drug delivery patch |
US6372228B1 (en) | 1994-11-15 | 2002-04-16 | Kenton W. Gregory | Method of producing elastin, elastin-based biomaterials and tropoelastin materials |
US6391049B1 (en) | 1999-10-06 | 2002-05-21 | Board Of Regents The University Of Texas System | Solid biodegradable device for use in tissue repair |
US6398972B1 (en) | 1999-04-12 | 2002-06-04 | Harvest Technologies Corporation | Method for producing platelet rich plasma and/or platelet concentrate |
US20020115066A1 (en) * | 1998-11-26 | 2002-08-22 | Hope Ralph Graham | Viral therapeutics |
US6443976B1 (en) | 1999-11-30 | 2002-09-03 | Akorn, Inc. | Methods for treating conditions and illnesses associated with abnormal vasculature |
US6461325B1 (en) | 1996-01-16 | 2002-10-08 | Baxter International Inc. | Fibrin delivery device and method for forming fibrin on a surface |
US20020187935A1 (en) * | 2000-02-11 | 2002-12-12 | Redmond Robert W. | Photochemical tissue bonding |
US20030003157A1 (en) * | 2001-06-06 | 2003-01-02 | University Of Medicine & Dentistry Of New Jersey | Collagen compositions and methods for making and using the same |
US6509028B2 (en) | 2000-06-26 | 2003-01-21 | Epicept Corporation | Methods and compositions for treating pain of the mucous membrane |
US20030060718A1 (en) * | 1999-09-10 | 2003-03-27 | Akorn, Inc. | Indocyanine green (ICG) compositions and related methods of use |
US20030064088A1 (en) * | 2001-08-29 | 2003-04-03 | Carvalho Ricardo Azevedo Pontes De | Implantable and sealable system for unidirectional delivery of therapeutic agents to tissues |
US6551618B2 (en) | 1994-03-15 | 2003-04-22 | University Of Birmingham | Compositions and methods for delivery of agents for neuronal regeneration and survival |
US20030077272A1 (en) * | 1996-09-23 | 2003-04-24 | Incept Llc | Proteinaceous gels having visualization agents and methods of use thereof |
US6573282B1 (en) | 1995-09-12 | 2003-06-03 | Adolor Corporation | Peripherally active anti-hyperalgesic opiates |
USRE38158E1 (en) | 1994-07-27 | 2003-06-24 | Minnesota Mining And Manufacturing Company | Adhesive sealant composition |
US6585773B1 (en) | 1998-08-21 | 2003-07-01 | Providence Health System-Oregon | Insertable stent and methods of making and using same |
US6607522B1 (en) | 2000-03-16 | 2003-08-19 | General Hospital Corporation | Methods for tissue welding using laser-activated protein solders |
US20030175323A1 (en) * | 2002-01-28 | 2003-09-18 | Utterberg David S. | High viscosity antibacterials for cannulae |
US6623959B2 (en) | 2001-06-13 | 2003-09-23 | Ethicon, Inc. | Devices and methods for cell harvesting |
US20030185870A1 (en) * | 2001-11-20 | 2003-10-02 | Grinstaff Mark W. | Interfacial biomaterials |
US20030190700A1 (en) * | 2001-04-24 | 2003-10-09 | Dennis Gonsalves | Synthetic nucleic acid molecule for imparting multiple traits |
US20030202956A1 (en) * | 1996-02-29 | 2003-10-30 | Closure Medical Corporation | Monomeric compositions effective as wound closure devices |
US6649888B2 (en) | 1999-09-23 | 2003-11-18 | Codaco, Inc. | Radio frequency (RF) heating system |
US6680063B1 (en) | 1999-10-08 | 2004-01-20 | Providence Health System-Oregon | Biocompatible albumin lamina and method |
US6682760B2 (en) | 2000-04-18 | 2004-01-27 | Colbar R&D Ltd. | Cross-linked collagen matrices and methods for their preparation |
US20040018226A1 (en) * | 1999-02-25 | 2004-01-29 | Wnek Gary E. | Electroprocessing of materials useful in drug delivery and cell encapsulation |
US6685730B2 (en) | 2001-09-26 | 2004-02-03 | Rice University | Optically-absorbing nanoparticles for enhanced tissue repair |
US20040037813A1 (en) * | 1999-02-25 | 2004-02-26 | Simpson David G. | Electroprocessed collagen and tissue engineering |
US20040049187A1 (en) * | 2000-10-23 | 2004-03-11 | Stuart Burnett | Self-adhesive hydratable matrix for topical therapeutic use |
US6706690B2 (en) | 1999-06-10 | 2004-03-16 | Baxter Healthcare Corporation | Hemoactive compositions and methods for their manufacture and use |
US20040058887A1 (en) * | 1999-08-31 | 2004-03-25 | Bowlin Gary L. | Electroprocessing in drug delivery and cell encapsulation |
US20040063613A1 (en) * | 1998-06-23 | 2004-04-01 | James Rolke | Methods and compositions for sealing tissue leaks |
US20040068266A1 (en) * | 2002-10-04 | 2004-04-08 | Yves Delmotte | Devices and methods for mixing and extruding medically useful compositions |
US6724958B1 (en) | 1998-01-23 | 2004-04-20 | Science & Engineering Associates, Inc. | Handheld laser system emitting visible non-visible radiation |
US20040116032A1 (en) * | 1999-02-25 | 2004-06-17 | Bowlin Gary L. | Electroprocessed collagen |
US6773699B1 (en) | 2001-10-09 | 2004-08-10 | Tissue Adhesive Technologies, Inc. | Light energized tissue adhesive conformal patch |
WO2004067044A2 (en) * | 2003-01-24 | 2004-08-12 | Rose-Hulman Institute Of Technology | Light-activated adhesive composite, system, and methods |
WO2004067045A2 (en) * | 2003-01-24 | 2004-08-12 | Rose-Hulman Institute Of Technology | Non-light activated adhesive composite, system, and methods |
US6780840B1 (en) | 2001-10-09 | 2004-08-24 | Tissue Adhesive Technologies, Inc. | Method for making a light energized tissue adhesive |
US6783546B2 (en) | 1999-09-13 | 2004-08-31 | Keraplast Technologies, Ltd. | Implantable prosthetic or tissue expanding device |
US6787357B2 (en) | 2000-09-01 | 2004-09-07 | Virginia Commonwealth University | Plasma-derived fibrin-based matrices and tissue |
US20040192643A1 (en) * | 1995-08-29 | 2004-09-30 | Fidia Advanced Biopolymers, S.R.L. | Biomaterials for preventing post-surgical adhesions comprised of hyaluronic acid derivatives |
WO2004087227A1 (en) * | 2003-04-04 | 2004-10-14 | Tissuemed Limited | Tissue-adhesive formulations |
US6808707B2 (en) | 2000-02-04 | 2004-10-26 | Matrix Design | Wound healing compositions and methods using tropoelastin and lysyl oxidase |
US20040215231A1 (en) * | 2000-02-03 | 2004-10-28 | David Fortune | Device for the closure of a surgical puncture |
US20040216181A1 (en) * | 1997-02-19 | 2004-10-28 | Sheng-Zhi Pang | Dna construct to confer multiple traits on plants |
US20040230185A1 (en) * | 2003-03-27 | 2004-11-18 | Cierra, Inc. | Energy based devices and methods for treatment of patent foramen ovale |
US20040229333A1 (en) * | 1999-02-25 | 2004-11-18 | Bowlin Gary L. | Electroprocessed fibrin-based matrices and tissues |
US20040254521A1 (en) * | 2003-06-16 | 2004-12-16 | Solx, Inc. | Shunt for the treatment of glaucoma |
US20040267191A1 (en) * | 2003-03-27 | 2004-12-30 | Cierra, Inc. | Methods and apparatus for treatment of patent foramen ovale |
US20050019264A1 (en) * | 1998-11-02 | 2005-01-27 | Xantech Pharmaceuticals, Inc. | Ultrasound contrast using halogenated xanthenes |
US20050021016A1 (en) * | 2003-03-27 | 2005-01-27 | Cierra, Inc. | Energy based devices and methods for treatment of anatomic tissue defects |
US6849092B2 (en) | 1999-09-13 | 2005-02-01 | Keraplast Technologies, Ltd. | Implantable prosthetic or tissue expanding device |
US20050034735A1 (en) * | 2003-03-27 | 2005-02-17 | Cierra, Inc. | Methods and apparatus for treatment of patent foramen ovale |
US20050038471A1 (en) * | 2000-02-11 | 2005-02-17 | Barbara Chan | Photochemical tissue bonding |
US20050042240A1 (en) * | 2002-01-28 | 2005-02-24 | Utterberg David S. | High viscosity antibacterials |
US20050049178A1 (en) * | 1999-07-06 | 2005-03-03 | Oberschwabenklinik Gmbh | Agent for the occlusion of blood vessels |
US20050069589A1 (en) * | 2003-07-23 | 2005-03-31 | Johan Lowinger | Tissue adhesive sealant |
US20050073131A1 (en) * | 2002-08-07 | 2005-04-07 | Markus Krumbeck | Combination of ski and ski binding |
US20050080406A1 (en) * | 2003-03-27 | 2005-04-14 | Cierra, Inc. | Energy based devices and methods for treatment of patent foramen ovale |
USRE38730E1 (en) * | 1995-05-05 | 2005-04-26 | Harvest Technologies Corporation | Automatic multiple-decanting centrifuge and method of treating physiological fluids |
WO2005037108A2 (en) * | 2003-10-21 | 2005-04-28 | Ramot At Tel Aviv University Ltd. | Compositions and devices including same useful for anastomosis |
US20050125015A1 (en) * | 2003-12-04 | 2005-06-09 | Mcnally-Heintzelman Karen M. | Tissue-handling apparatus, system and method |
US20050125033A1 (en) * | 2003-12-04 | 2005-06-09 | Mcnally-Heintzelman Karen M. | Wound closure apparatus |
US20050165385A1 (en) * | 2004-01-22 | 2005-07-28 | Solx, Inc. | Glaucoma treatment method |
US6939364B1 (en) * | 2001-10-09 | 2005-09-06 | Tissue Adhesive Technologies, Inc. | Composite tissue adhesive |
EP1272119A4 (en) * | 2000-02-11 | 2005-09-14 | Gen Hospital Corp | Photochemical tissue bonding |
USRE38827E1 (en) | 1994-07-27 | 2005-10-11 | 3M Innovative Properties Company | Adhesive sealant composition |
US20050228283A1 (en) * | 2003-06-10 | 2005-10-13 | Gifford Hanson S | Methods and apparatus for non-invasively treating atrial fibrillation using high intensity focused ultrasound |
US20060009801A1 (en) * | 2004-07-08 | 2006-01-12 | Mcgurk Erin | Pleural effusion treatment device, method and material |
US20060024372A1 (en) * | 2004-07-29 | 2006-02-02 | Utterberg David S | High viscosity antibacterials |
US7001328B1 (en) * | 1994-11-15 | 2006-02-21 | Kenton W. Gregory | Method for using tropoelastin and for producing tropoelastin biomaterials |
US20060074410A1 (en) * | 2004-06-21 | 2006-04-06 | Cierra, Inc. | Energy based devices and methods for treatment of anatomic tissue defects |
US7025776B1 (en) | 2001-04-24 | 2006-04-11 | Advanced Catheter Engineering, Inc. | Arteriotomy closure devices and techniques |
US20060089715A1 (en) * | 2004-06-07 | 2006-04-27 | Csaba Truckai | Implants and methods for treating bone |
US20060094865A1 (en) * | 2004-10-29 | 2006-05-04 | Kapur Terri A | Intraoperative method for isolating and concentrating autologous growth factors and for forming residual autologous growth factor compositions |
US20060106459A1 (en) * | 2004-08-30 | 2006-05-18 | Csaba Truckai | Bone treatment systems and methods |
US20060147409A1 (en) * | 1996-09-23 | 2006-07-06 | Incept Llc | Biocompatible crosslinked polymers with visualization agents |
US20060167561A1 (en) * | 2003-06-05 | 2006-07-27 | Johann Odar | Methods for repairing and regenerating human dura mater |
US20060178743A1 (en) * | 2005-02-10 | 2006-08-10 | Spine Wave, Inc. | Synovial fluid barrier |
US7122620B1 (en) | 1998-05-27 | 2006-10-17 | Medical Research Services And Development Ltd. | Haptotactic peptides |
US7138441B1 (en) | 1999-05-29 | 2006-11-21 | United States Surgical Corporation | Bioabsorbable blends and surgical articles therefrom |
US20060264965A1 (en) * | 2004-11-05 | 2006-11-23 | Shadduck John H | Bone treatment systems and methods |
US20060271089A1 (en) * | 2005-04-11 | 2006-11-30 | Cierra, Inc. | Methods and apparatus to achieve a closure of a layered tissue defect |
US20070003480A1 (en) * | 2002-11-03 | 2007-01-04 | Hapto Biotech, Inc. | Liposomal composition comprising haptotactic peptides |
US20070123852A1 (en) * | 2003-03-27 | 2007-05-31 | Cierra, Inc. | Methods and apparatus for closing a layered tissue defect |
US7226657B1 (en) | 1998-11-04 | 2007-06-05 | Baxter International Inc. | Element provided with a fibrin layer, preparation and use thereof |
US20070233250A1 (en) * | 2006-02-07 | 2007-10-04 | Shadduck John H | Systems for treating bone |
US7303757B2 (en) | 2002-08-06 | 2007-12-04 | Matrix Medical, Llc | Biocompatible phase invertable proteinaceous compositions and methods for making and using the same |
US20070286891A1 (en) * | 2004-08-03 | 2007-12-13 | Tissuemed Limited | Tissue-Adhesive Materials |
US7320962B2 (en) | 1996-08-27 | 2008-01-22 | Baxter International Inc. | Hemoactive compositions and methods for their manufacture and use |
US20080026032A1 (en) * | 2006-07-27 | 2008-01-31 | Zubery Yuval | Composite implants for promoting bone regeneration and augmentation and methods for their preparation and use |
US7351422B2 (en) | 2000-02-22 | 2008-04-01 | Hogy Medical Co., Ltd. | Hemostatic soluble cellulose fibers containing coagulating protein for treating wound and process for producing the same |
US20080095736A1 (en) * | 1998-12-04 | 2008-04-24 | Incept Llc | Biocompatible polymers and hydrogels and methods of use |
US20080140069A1 (en) * | 2006-12-07 | 2008-06-12 | Cierra, Inc. | Multi-electrode apparatus for tissue welding and ablation |
EP0862468B2 (en) † | 1996-10-07 | 2008-07-23 | Imedex Biomateriaux | Adhesive composition with macromolecular polyaldehyde base and method for cross-linking collagen |
US20080188858A1 (en) * | 2007-02-05 | 2008-08-07 | Robert Luzzi | Bone treatment systems and methods |
US20080187591A1 (en) * | 2006-08-02 | 2008-08-07 | Baxter International, Inc. | Rapidly acting dry sealant and methods for use and manufacture |
US20080260802A1 (en) * | 1996-09-23 | 2008-10-23 | Sawhney Amarpreet S | Biocompatible hydrogels made with small molecule precursors |
US20080267902A1 (en) * | 2007-04-27 | 2008-10-30 | Hillary Enyart | Blood products with binding agent |
US20080286376A1 (en) * | 2001-07-17 | 2008-11-20 | Fusion Medical Technologies, Inc. | Dry hemostatic compositions and methods for their preparation |
US20090012525A1 (en) * | 2005-09-01 | 2009-01-08 | Eric Buehlmann | Devices and systems for delivering bone fill material |
US20090030451A1 (en) * | 2005-02-09 | 2009-01-29 | Hadba Ahmad R | Synthetic Sealants |
US20090092651A1 (en) * | 2007-10-05 | 2009-04-09 | Bhavin Shah | Absorbable adhesives and their formulation for use in medical applications |
US20090143500A1 (en) * | 2007-12-03 | 2009-06-04 | Ronald Dieck | Biocompatible phase invertible proteinaceous compositions and methods for making and using the same |
US20090155197A1 (en) * | 2007-12-14 | 2009-06-18 | Smith Molly K | Goniochromic indicator for skin sealant |
EP2080520A1 (en) | 2001-02-23 | 2009-07-22 | The Scripps Research Institute | Tryptophanyl-tRNA synthetase derived polypeptides useful for the regulation of angiogenesis |
US20090227981A1 (en) * | 2007-03-05 | 2009-09-10 | Bennett Steven L | Low-Swelling Biocompatible Hydrogels |
US20090227689A1 (en) * | 2007-03-05 | 2009-09-10 | Bennett Steven L | Low-Swelling Biocompatible Hydrogels |
US20090247664A1 (en) * | 2008-02-01 | 2009-10-01 | Dfine, Inc. | Bone treatment systems and methods |
US20090324721A1 (en) * | 1996-09-23 | 2009-12-31 | Jack Kennedy | Hydrogels Suitable For Use In Polyp Removal |
US20100016467A1 (en) * | 2008-02-01 | 2010-01-21 | Dfine, Inc. | Bone treatment systems and methods |
US20100028309A1 (en) * | 2006-05-31 | 2010-02-04 | Baxter International Inc. | Method for directed cell in-growth and controlled tissue regeneration in spinal surgery |
US20100029913A1 (en) * | 2002-08-06 | 2010-02-04 | Kemal Schankereli | Biocompatible phase invertible proteinaceous compositions and methods for making and using the same |
US20100144590A1 (en) * | 2002-08-06 | 2010-06-10 | Kemal Schankereli | Biocompatible phase invertable proteinaceous compositions and methods for making and using the same |
US20100183582A1 (en) * | 2003-08-07 | 2010-07-22 | Ethicon, Inc. | Hemostatic compositions containing sterile thrombin |
US20100203033A1 (en) * | 2007-07-02 | 2010-08-12 | Israel Nur | Kits, formulations and solutions having enzymatically- permissive amounts of visualization agents and uses thereof |
US20100209478A1 (en) * | 2009-02-12 | 2010-08-19 | Sawhney Amarpreet S | Drug delivery through hydrogel plugs |
WO2010121051A1 (en) | 2009-04-17 | 2010-10-21 | Tenaxis Medical, Inc. | Biocompatible phase invertible proteinaceous compositions and methods for making and using the same |
US20100292717A1 (en) * | 2009-05-18 | 2010-11-18 | Baxter International Inc. | Method for the improvement of mesh implant biocompatibility |
US20100318048A1 (en) * | 2009-06-16 | 2010-12-16 | Baxter International Inc. | Hemostatic sponge |
US7871637B2 (en) | 1996-08-27 | 2011-01-18 | Baxter International Inc. | Dry hemostatic compositions and methods for their preparation |
US20110027335A1 (en) * | 2007-08-10 | 2011-02-03 | Tissuemed Limited | Coated medical devices |
US20110054482A1 (en) * | 2004-06-09 | 2011-03-03 | Dfine, Inc. | Composites and methods for treating bone |
US7972330B2 (en) | 2003-03-27 | 2011-07-05 | Terumo Kabushiki Kaisha | Methods and apparatus for closing a layered tissue defect |
US20110171731A1 (en) * | 2008-09-16 | 2011-07-14 | Dietz Allan B | Compositions containing platelet contents |
US20110184407A1 (en) * | 2010-01-26 | 2011-07-28 | Tyco Healthcare Group Lp | Hernia Repair System |
US20110202026A1 (en) * | 2009-12-16 | 2011-08-18 | Baxter International Inc. | Hemostatic sponge |
US8067031B2 (en) | 2004-04-28 | 2011-11-29 | Angiodevice International Gmbh | Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use |
US8133336B2 (en) | 2006-02-03 | 2012-03-13 | Tissuemed Limited | Tissue-adhesive materials |
US8226708B1 (en) * | 1999-03-03 | 2012-07-24 | Trivascular, Inc. | Inflatable intraluminal graft |
WO2012135808A2 (en) * | 2011-04-01 | 2012-10-04 | The Johns Hopkins University | Intraoperative and blood-derived adhesives |
US8303981B2 (en) | 1996-08-27 | 2012-11-06 | Baxter International Inc. | Fragmented polymeric compositions and methods for their use |
US8357378B2 (en) | 1996-08-27 | 2013-01-22 | Baxter International Inc. | Fragmented polymeric compositions and methods for their use |
WO2013119880A1 (en) | 2012-02-07 | 2013-08-15 | Global Bio Therapeutics Usa, Inc. | Compartmentalized method of nucleic acid delivery and compositions and uses thereof |
US8518063B2 (en) | 2001-04-24 | 2013-08-27 | Russell A. Houser | Arteriotomy closure devices and techniques |
US20130281913A1 (en) * | 2012-04-20 | 2013-10-24 | Klox Technologies Inc. | Biophotonic compositions and methods for providing biophotonic treatment |
US8603511B2 (en) | 1996-08-27 | 2013-12-10 | Baxter International, Inc. | Fragmented polymeric compositions and methods for their use |
US8703170B2 (en) | 2010-04-07 | 2014-04-22 | Baxter International Inc. | Hemostatic sponge |
US8790698B2 (en) | 2007-10-30 | 2014-07-29 | Baxter International Inc. | Use of a regenerative biofunctional collagen biomatrix for treating visceral or parietal defects |
US20140243675A1 (en) * | 2000-11-20 | 2014-08-28 | Senorx, Inc. | Tissue site markers for in vivo imaging |
US8940335B2 (en) | 2010-06-01 | 2015-01-27 | Baxter International Inc. | Process for making dry and stable hemostatic compositions |
US8961541B2 (en) | 2007-12-03 | 2015-02-24 | Cardio Vascular Technologies Inc. | Vascular closure devices, systems, and methods of use |
US8992567B1 (en) | 2001-04-24 | 2015-03-31 | Cardiovascular Technologies Inc. | Compressible, deformable, or deflectable tissue closure devices and method of manufacture |
US8999376B2 (en) | 2012-02-03 | 2015-04-07 | Xcede Technologies, Inc. | Tissue patch |
US9045600B2 (en) | 2009-05-13 | 2015-06-02 | Keraplast Technologies, Ltd. | Biopolymer materials |
US20150157439A1 (en) * | 2013-12-09 | 2015-06-11 | Boston Scientific Scimed, Inc. | Compositions, devices, kits and methods for attaching surgical meshes to tissue |
US9084728B2 (en) | 2010-06-01 | 2015-07-21 | Baxter International Inc. | Process for making dry and stable hemostatic compositions |
US9265858B2 (en) | 2012-06-12 | 2016-02-23 | Ferrosan Medical Devices A/S | Dry haemostatic composition |
US9345460B2 (en) | 2001-04-24 | 2016-05-24 | Cardiovascular Technologies, Inc. | Tissue closure devices, device and systems for delivery, kits and methods therefor |
US9408945B2 (en) | 2010-06-01 | 2016-08-09 | Baxter International Inc. | Process for making dry and stable hemostatic compositions |
US9433700B2 (en) | 2009-04-27 | 2016-09-06 | Medibeacon Inc. | Tissue sealant compositions, vascular closure devices, and uses thereof |
US9533069B2 (en) | 2008-02-29 | 2017-01-03 | Ferrosan Medical Devices A/S | Device for promotion of hemostasis and/or wound healing |
US9540548B1 (en) | 2015-08-07 | 2017-01-10 | Xcede Technologies, Inc. | Adhesive compositions and related methods |
US9655707B2 (en) | 2014-02-06 | 2017-05-23 | Boston Scientific Scimed, Inc. | Methods, compositions, devices and kits for attaching surgical slings to tissue |
US9724078B2 (en) | 2013-06-21 | 2017-08-08 | Ferrosan Medical Devices A/S | Vacuum expanded dry composition and syringe for retaining same |
US9775906B2 (en) | 2007-07-09 | 2017-10-03 | Incept Llc | Hydrogel polymeric compositions and methods |
US9821025B2 (en) | 2011-10-11 | 2017-11-21 | Baxter International Inc. | Hemostatic compositions |
US9833541B2 (en) | 2011-10-27 | 2017-12-05 | Baxter International Inc. | Hemostatic compositions |
US9833538B2 (en) | 2015-08-07 | 2017-12-05 | Xcede Technologies, Inc. | Adhesive compositions and related methods |
US10098981B2 (en) | 2002-08-06 | 2018-10-16 | Baxter International Inc. | Biocompatible phase invertable proteinaceous compositions and methods for making and using the same |
US10111980B2 (en) | 2013-12-11 | 2018-10-30 | Ferrosan Medical Devices A/S | Dry composition comprising an extrusion enhancer |
US10130706B2 (en) | 2013-03-14 | 2018-11-20 | Klox Technologies Inc. | Biophotonic materials and uses thereof |
US10207029B2 (en) | 2014-04-01 | 2019-02-19 | Klox Technologies Inc. | Tissue filler compositions and methods of use |
US10292381B2 (en) | 2012-07-20 | 2019-05-21 | The General Hospital Corporation | Vessel treatment systems, methods, and kits |
US10322170B2 (en) | 2011-10-11 | 2019-06-18 | Baxter International Inc. | Hemostatic compositions |
US10342635B2 (en) | 2005-04-20 | 2019-07-09 | Bard Peripheral Vascular, Inc. | Marking device with retractable cannula |
WO2019135237A1 (en) * | 2018-01-04 | 2019-07-11 | Ramot At Tel-Aviv University Ltd. | Scaffold for tissue welding |
US10478284B2 (en) | 2012-07-20 | 2019-11-19 | The General Hospital Corporation | Methods for tissue passivation |
WO2019231763A1 (en) | 2018-05-27 | 2019-12-05 | Christos Angeletakis | Tissue adhesives and sealants using naturally derived aldehydes |
US10549112B2 (en) | 2012-07-20 | 2020-02-04 | The General Hospital Corporation | Apparatus for tissue irradiation and methods and kits utilizing the same |
US10588998B2 (en) | 2015-08-07 | 2020-03-17 | Xcede Technologies, Inc. | Adhesive compositions and related methods |
US10653837B2 (en) | 2014-12-24 | 2020-05-19 | Ferrosan Medical Devices A/S | Syringe for retaining and mixing first and second substances |
US10849652B2 (en) | 2010-10-05 | 2020-12-01 | Emory University | Devices, systems, and methods for improving access to cardiac and vascular chambers |
US10881736B2 (en) | 2013-07-03 | 2021-01-05 | Klox Technologies Inc. | Biophotonic compositions comprising a chromophore and a gelling agent for treating wounds |
US10918796B2 (en) | 2015-07-03 | 2021-02-16 | Ferrosan Medical Devices A/S | Syringe for mixing two components and for retaining a vacuum in a storage condition |
US11046818B2 (en) | 2014-10-13 | 2021-06-29 | Ferrosan Medical Devices A/S | Dry composition for use in haemostasis and wound healing |
US11109849B2 (en) | 2012-03-06 | 2021-09-07 | Ferrosan Medical Devices A/S | Pressurized container containing haemostatic paste |
US11116841B2 (en) | 2012-04-20 | 2021-09-14 | Klox Technologies Inc. | Biophotonic compositions, kits and methods |
CN113876997A (en) * | 2021-09-27 | 2022-01-04 | 广东省科学院健康医学研究所 | Albumin composite adhesive and preparation method thereof |
US11350625B2 (en) | 2013-07-18 | 2022-06-07 | The General Hospital Corporation | Vessel treatment systems, methods, and kits |
US11364032B2 (en) | 2013-08-08 | 2022-06-21 | Global Bio Therapeutics, Inc. | Clamp device for minimally invasive procedures and uses thereof |
US11369591B2 (en) | 2015-05-12 | 2022-06-28 | Incept, Llc | Drug delivery from hydrogels |
US11389663B2 (en) * | 2011-04-01 | 2022-07-19 | Bioregentech, Inc. | Laser assisted wound healing protocol and system |
US11421349B2 (en) | 2014-10-31 | 2022-08-23 | Klox Technologies Inc. | Photoactivatable fibers and fabric media |
US11654293B2 (en) * | 2016-11-10 | 2023-05-23 | The Bioregentech Institute, Inc. | Laser assisted wound healing protocol and system |
US11730760B2 (en) | 2011-04-01 | 2023-08-22 | The Bioregentech Institute, Inc. | Laser assisted wound healing protocol and system |
US11739166B2 (en) | 2020-07-02 | 2023-08-29 | Davol Inc. | Reactive polysaccharide-based hemostatic agent |
TWI814462B (en) * | 2021-08-24 | 2023-09-01 | 國立臺灣大學 | Manufacturing method of hemostatic material and hemostatic material prepared thereby |
US11745026B2 (en) | 2011-04-01 | 2023-09-05 | The Bioregentech Institute, Inc. | Laser assisted wound healing protocol and system |
US11779431B2 (en) | 2008-12-30 | 2023-10-10 | C. R. Bard, Inc. | Marker delivery device for tissue marker placement |
US11801324B2 (en) | 2018-05-09 | 2023-10-31 | Ferrosan Medical Devices A/S | Method for preparing a haemostatic composition |
US11891620B2 (en) | 2014-05-16 | 2024-02-06 | Mayo Foundation For Medical Education And Research | Cell culture media compositions for primary cells |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5510418A (en) * | 1988-11-21 | 1996-04-23 | Collagen Corporation | Glycosaminoglycan-synthetic polymer conjugates |
US5197973A (en) * | 1990-12-14 | 1993-03-30 | Creative Biomolecules, Inc. | Synthetic bioadhesive |
US5749895A (en) * | 1991-02-13 | 1998-05-12 | Fusion Medical Technologies, Inc. | Method for bonding or fusion of biological tissue and material |
US6440427B1 (en) | 1991-06-17 | 2002-08-27 | Biovitrum Ab | Tissue treatment composition comprising fibrin or fibrinogen and biodegradable and biocompatible polymer |
SE9101853D0 (en) * | 1991-06-17 | 1991-06-17 | Jonas Wadstroem | IMPROVED TISSUE ASHESIVE |
GB9211432D0 (en) * | 1992-05-29 | 1992-07-15 | Jevco Ltd | Absorbable bone sealant |
US5552452A (en) * | 1993-03-15 | 1996-09-03 | Arch Development Corp. | Organic tissue glue for closure of wounds |
GB2284606A (en) * | 1993-11-24 | 1995-06-14 | Aspid S A De C V | Polymerised collagen-based anti-fibroid composition |
CA2301799C (en) * | 1997-11-07 | 2007-08-07 | Conjuchem, Inc. | Novel conjugates of opioids and endogenous carriers |
WO2000012018A1 (en) * | 1998-08-26 | 2000-03-09 | Advanced Closure Systems, Inc. | Compositions, systems, and methods for creating in situ, chemically cross-linked, mechanical barriers or covering structures |
JP2002058736A (en) * | 2000-08-17 | 2002-02-26 | Seikagaku Kogyo Co Ltd | Composition, medical instrument and kit for bone implantation |
EP1430090A4 (en) | 2001-08-31 | 2006-10-11 | Keratec Ltd | The production of biopolymer film, fibre, foam and adhesive materials from soluble s-sulfonated keratin derivatives |
BR0311723A (en) | 2002-06-10 | 2005-03-01 | Keratec Ltd | Keratin-derived orthopedic materials |
US7273896B2 (en) * | 2003-04-10 | 2007-09-25 | Angiotech Pharmaceuticals (Us), Inc. | Compositions and methods of using a transient colorant |
US7767756B2 (en) | 2003-09-19 | 2010-08-03 | Keraplast Technologies, Ltd. | Composite materials containing keratin |
EP1694370B1 (en) | 2003-12-19 | 2012-08-22 | Keratec Limited | Wound care products containing keratin |
US9029349B2 (en) | 2004-08-27 | 2015-05-12 | Antonio Lauto | Bioadhesive for tissue repair |
JP2006158611A (en) * | 2004-12-07 | 2006-06-22 | Hamamatsu Univ School Of Medicine | Indocyanine green quantitative catheter system |
US7579317B2 (en) | 2005-03-11 | 2009-08-25 | Keratec, Ltd. | Nutraceutical composition comprising soluble keratin or derivative thereof |
DE102006011211A1 (en) * | 2006-03-02 | 2007-09-06 | Ossacur Ag | Material for the treatment of bone and / or cartilage defects |
CA2672069A1 (en) | 2006-12-06 | 2008-06-12 | Keratec, Ltd. | Bone void fillers and methods of making the same |
CA2672529A1 (en) | 2006-12-11 | 2008-06-19 | Keratec, Ltd. | Porous keratin construct and method of making the same |
CN101711168B (en) | 2007-04-13 | 2013-05-01 | 库罗斯生物外科股份公司 | Polymeric tissue sealant |
Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3438374A (en) * | 1966-02-28 | 1969-04-15 | Us Health Education & Welfare | Method of bonding tissue surfaces and controlling hemorrhaging thereof using a tissue adhesive and hemostatic composition |
US4122853A (en) * | 1977-03-14 | 1978-10-31 | Spectra-Med | Infrared laser photocautery device |
US4362567A (en) * | 1979-02-15 | 1982-12-07 | Immuno Aktiengesellschaft Fur Chemisch-Medizinische Produkte | Tissue adhesive |
US4550238A (en) * | 1982-11-05 | 1985-10-29 | Warner-Lambert Company | Apparatus and method for sealing capsules |
US4625724A (en) * | 1984-07-25 | 1986-12-02 | Fuji Photo Optical Co., Ltd. | Laser vascular anastomosis apparatus |
US4633870A (en) * | 1985-06-26 | 1987-01-06 | Sauer Jude S | Apparatus for effecting anastomosis of tubular tissue by laser welding |
US4657820A (en) * | 1986-04-16 | 1987-04-14 | Gregory Halpern | Plastic article containing a top coat comprising an albumin and polysaccharide mixture |
US4672969A (en) * | 1983-10-06 | 1987-06-16 | Sonomo Corporation | Laser healing method |
US4676790A (en) * | 1985-09-25 | 1987-06-30 | Kern Seymour P | Method of manufacture and implantation of corneal inlays |
US4782819A (en) * | 1987-02-25 | 1988-11-08 | Adair Edwin Lloyd | Optical catheter |
US4818291A (en) * | 1986-12-10 | 1989-04-04 | Ajinomoto Co., Inc. | Silk-fibroin and human-fibrinogen adhesive composition |
US4854320A (en) * | 1983-10-06 | 1989-08-08 | Laser Surgery Software, Inc. | Laser healing method and apparatus |
US4909251A (en) * | 1988-05-31 | 1990-03-20 | Immuno Aktiengesellschaft Fur Chemisch-Medizinische Produkte | Tissue adhesive |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4280954A (en) * | 1975-07-15 | 1981-07-28 | Massachusetts Institute Of Technology | Crosslinked collagen-mucopolysaccharide composite materials |
GB1515963A (en) * | 1975-07-15 | 1978-06-28 | Massachusetts Inst Technology | Crosslinked collagen-mucopolysaccharide composite materials |
US4167045A (en) * | 1977-08-26 | 1979-09-11 | Interface Biomedical Laboratories Corp. | Cardiac and vascular prostheses |
AT359653B (en) * | 1979-02-15 | 1980-11-25 | Immuno Ag | METHOD FOR PRODUCING A TISSUE ADHESIVE |
CA1213520A (en) * | 1982-03-17 | 1986-11-04 | Abe Widra | Hydrophilic biopolymeric copolyelectrolytes, and biodegradable dressings comprising same |
IL74179A (en) * | 1984-01-30 | 1992-05-25 | Meadox Medicals Inc | Collagen synthetic vascular graft |
JPH06102628B2 (en) * | 1984-03-27 | 1994-12-14 | イムノ・アクチエンゲゼルシャフト | Tissue adhesive manufacturing method |
CA1294546C (en) * | 1986-04-23 | 1992-01-21 | John S. Sundsmo | Wound healing composition containing collagen |
EP0246638A3 (en) * | 1986-05-23 | 1989-03-15 | Cordis Corporation | Biologically modified synthetic grafts |
JPS6485272A (en) * | 1986-12-10 | 1989-03-30 | Ajinomoto Kk | Adhesive |
JPH01124465A (en) * | 1987-11-10 | 1989-05-17 | Kanegafuchi Chem Ind Co Ltd | Composition for artificial basement membrane and implantation device with artificial basement membrane |
JPH01265970A (en) * | 1988-04-19 | 1989-10-24 | Shiseido Co Ltd | Collagen water solution or water dispersion solution including hyaluronic acid |
US4950483A (en) * | 1988-06-30 | 1990-08-21 | Collagen Corporation | Collagen wound healing matrices and process for their production |
-
1991
- 1991-07-09 US US07/727,607 patent/US5292362A/en not_active Expired - Lifetime
- 1991-07-23 ES ES91915440T patent/ES2137930T3/en not_active Expired - Lifetime
- 1991-07-23 EP EP91915440A patent/EP0542880B1/en not_active Revoked
- 1991-07-23 AU AU84979/91A patent/AU8497991A/en not_active Abandoned
- 1991-07-23 AT AT91915440T patent/ATE183656T1/en not_active IP Right Cessation
- 1991-07-23 CA CA002087957A patent/CA2087957C/en not_active Expired - Lifetime
- 1991-07-23 WO PCT/US1991/005186 patent/WO1992002238A1/en not_active Application Discontinuation
- 1991-07-23 JP JP3514745A patent/JPH06507376A/en active Pending
- 1991-07-23 DE DE69131556T patent/DE69131556T2/en not_active Revoked
Patent Citations (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3438374A (en) * | 1966-02-28 | 1969-04-15 | Us Health Education & Welfare | Method of bonding tissue surfaces and controlling hemorrhaging thereof using a tissue adhesive and hemostatic composition |
US4122853A (en) * | 1977-03-14 | 1978-10-31 | Spectra-Med | Infrared laser photocautery device |
US4362567A (en) * | 1979-02-15 | 1982-12-07 | Immuno Aktiengesellschaft Fur Chemisch-Medizinische Produkte | Tissue adhesive |
US4414976A (en) * | 1979-02-15 | 1983-11-15 | Immuno Aktiengesellschaft Fur Chemischmedizinische Produkte | Tissue adhesive |
US4550238A (en) * | 1982-11-05 | 1985-10-29 | Warner-Lambert Company | Apparatus and method for sealing capsules |
US4672969A (en) * | 1983-10-06 | 1987-06-16 | Sonomo Corporation | Laser healing method |
US4854320A (en) * | 1983-10-06 | 1989-08-08 | Laser Surgery Software, Inc. | Laser healing method and apparatus |
US4625724A (en) * | 1984-07-25 | 1986-12-02 | Fuji Photo Optical Co., Ltd. | Laser vascular anastomosis apparatus |
US4633870A (en) * | 1985-06-26 | 1987-01-06 | Sauer Jude S | Apparatus for effecting anastomosis of tubular tissue by laser welding |
US4676790A (en) * | 1985-09-25 | 1987-06-30 | Kern Seymour P | Method of manufacture and implantation of corneal inlays |
US4657820A (en) * | 1986-04-16 | 1987-04-14 | Gregory Halpern | Plastic article containing a top coat comprising an albumin and polysaccharide mixture |
US4818291A (en) * | 1986-12-10 | 1989-04-04 | Ajinomoto Co., Inc. | Silk-fibroin and human-fibrinogen adhesive composition |
US4782819A (en) * | 1987-02-25 | 1988-11-08 | Adair Edwin Lloyd | Optical catheter |
US4909251A (en) * | 1988-05-31 | 1990-03-20 | Immuno Aktiengesellschaft Fur Chemisch-Medizinische Produkte | Tissue adhesive |
Non-Patent Citations (81)
Title |
---|
A. F. S. Flemming et al "Laser assisted Microvascular Anastomosis---" Br. J. Plast Surg 41: 378-388 (1988) (no month avail). |
A. F. S. Flemming et al Laser assisted Microvascular Anastomosis Br. J. Plast Surg 41: 378 388 (1988) (no month avail). * |
A. Henrick et al "Organic Tissue Glue in the Closure of Cataract incisions" J. Cat. Ref. Surg vol. 13:551-53 (1987) (no month avail.). |
A. Henrick et al Organic Tissue Glue in the Closure of Cataract incisions J. Cat. Ref. Surg vol. 13:551 53 (1987) (no month avail.). * |
A. Hjortrup et al "Fibrin Adhesive versus sutured Anastomosis . . . " Br. J. Surg vol. 73 :760-761 (Sep. 1986). |
A. Hjortrup et al Fibrin Adhesive versus sutured Anastomosis . . . Br. J. Surg vol. 73 :760 761 (Sep. 1986). * |
B. A. Lowe et al "Vasovasostomy in the Murine Vas Deferens---" Lasers in Surg ± Med 8:377-380 (1988) (no month avail.). |
B. A. Lowe et al Vasovasostomy in the Murine Vas Deferens Lasers in Surg Med 8:377 380 (1988) (no month avail.). * |
B. Jean et al "Target dyes in Ophthalmology Part I" Laser in light in Opth. vol. 3 No. 1 pp. 39-45 (1990) (no month avail.). |
B. Jean et al Target dyes in Ophthalmology Part I Laser in light in Opth. vol. 3 No. 1 pp. 39 45 (1990) (no month avail.). * |
C. S. Kischkel et al "Target dyes in opthalmology Part II" Lasers in light in Opth. vol. 3 No. 1 pp. 47-52 (1990) (no month avail.). |
C. S. Kischkel et al Target dyes in opthalmology Part II Lasers in light in Opth. vol. 3 No. 1 pp. 47 52 (1990) (no month avail.). * |
CA85(19):138042h, Gorog et al, 1976 (no month avail.). * |
D. F. Thompson et al "Fibrin Glue: A review of its Preparation, Efficacy and adverse effects---" Drug. Int. ±Clin. Pharm 22:946-95 (1988) (no month avail.). |
D. F. Thompson et al Fibrin Glue: A review of its Preparation, Efficacy and adverse effects Drug. Int. Clin. Pharm 22:946 95 (1988) (no month avail.). * |
D. J. Coleman Et al "A Biologic Tissue Adhesive for vitreoretinal surgery" Retina vol. 8 No. 4:250-256 (1986-88) (no month avail.). |
D. J. Coleman Et al A Biologic Tissue Adhesive for vitreoretinal surgery Retina vol. 8 No. 4:250 256 (1986 88) (no month avail.). * |
D. Miller et al "Healon a guide to its use in Opthalmic surgery" pp. 5-28 (no date avail.). |
D. Miller et al Healon a guide to its use in Opthalmic surgery pp. 5 28 (no date avail.). * |
D. P. Poppas et al "Laser welding in Urethral surgery . . . "J. Uralogy vol. 139:415-417 (1987-88) (no month avail.). |
D. P. Poppas et al Laser welding in Urethral surgery . . . J. Uralogy vol. 139:415 417 (1987 88) (no month avail.). * |
E. L. Smith et al Principles of Biochemistry 7th Edition pp. 7 and 229 (1983) (no month avail.). * |
F. X. Brunner "Histological findings in sutured and fibrin-glued Microvascular Anastomosis" A. Otor. 240;311-318 (1984) (no month avail.). |
F. X. Brunner Histological findings in sutured and fibrin glued Microvascular Anastomosis A. Otor. 240;311 318 (1984) (no month avail.). * |
G. E. Kopchock et al "co2 and Argon Laser Vascular Welding---" Laser in Surg ± Med 8:584-588 (1988) (no month avail.). |
G. E. Kopchock et al co2 and Argon Laser Vascular Welding Laser in Surg Med 8:584 588 (1988) (no month avail.). * |
G. F. Gestring et al "Autologoos Fibrinogen for tissue adhesion . . . " Vas. Surg pp. 294-304 (Sep./Oct. 1983). |
G. F. Gestring et al Autologoos Fibrinogen for tissue adhesion . . . Vas. Surg pp. 294 304 (Sep./Oct. 1983). * |
G. S. Ganesan et al "Urethral Reconstruction using the Carbon Dioxide Laser---" J. Urol. vol. 142; 1139-1141 (1989) (no month avail.). |
G. S. Ganesan et al Urethral Reconstruction using the Carbon Dioxide Laser J. Urol. vol. 142; 1139 1141 (1989) (no month avail.). * |
H. Zauberman et al "Use of Fibrin Glue in ocular Surgery" Opth. Surg vol. 19 No. 2: 132-133 (1988) (no month avail.). |
H. Zauberman et al Use of Fibrin Glue in ocular Surgery Opth. Surg vol. 19 No. 2: 132 133 (1988) (no month avail.). * |
I. K. Arenberg et al "Autologous Fibrin Glue and Sealant---"OT. surg vol. 101 No. 6:709-712 (1989) (no month avail.). |
I. K. Arenberg et al Autologous Fibrin Glue and Sealant OT. surg vol. 101 No. 6:709 712 (1989) (no month avail.). * |
J. A. Fayez et al "Comparison of Tubal Surgery with the co2 Laser . . . " Fert. and Ster. vol. 40 No. 4 (Oct. 1983). |
J. A. Fayez et al Comparison of Tubal Surgery with the co2 Laser . . . Fert. and Ster. vol. 40 No. 4 (Oct. 1983). * |
J. A. Fayez et al Tubal Microsurgery with the Carbon dioxide Laser Am. J. obster. Gynecol 146/4 (1983) (no month avail.). * |
J. E. Bailes et al "Review of Tissue Welding Application in Neurosurgery" Microsurgery 8;242-244 (1987) (no month avail.). |
J. E. Bailes et al Review of Tissue Welding Application in Neurosurgery Microsurgery 8;242 244 (1987) (no month avail.). * |
J. K. Choe et al "Clinical and Histological evaluation of Laser Reanastomosis . . . " Fert. and Ster. vol. 41 No. 5 (May 1984). |
J. K. Choe et al Clinical and Histological evaluation of Laser Reanastomosis . . . Fert. and Ster. vol. 41 No. 5 (May 1984). * |
J. S. Saver et al "Bursting Pressures of CO2 Laser-Welded Rabbit Ileum" Lasers in Surg ± Med 6:106-109 (1986) (no month avail.). |
J. S. Saver et al "the first sutureless, Laser-welded, end-to end Bowel/Anastomosis" Lasers in surg. ± Med. 9:70-73 (no month avail.). |
J. S. Saver et al Bursting Pressures of CO2 Laser Welded Rabbit Ileum Lasers in Surg Med 6:106 109 (1986) (no month avail.). * |
J. S. Saver et al the first sutureless, Laser welded, end to end Bowel/Anastomosis Lasers in surg. Med. 9:70 73 (no month avail.). * |
J. W. Baker et al "A technique for spray application of Fibrin Glue . . . " Ann. Thorac. Surg 43:564-65 (May 1987). |
J. W. Baker et al A technique for spray application of Fibrin Glue . . . Ann. Thorac. Surg 43:564 65 (May 1987). * |
K. H. Siedentor et al "Autologous Fibrin Tissue Adhesive" Laryngoscope 95:1074-1076 (Sep. 1985). |
K. H. Siedentor et al Autologous Fibrin Tissue Adhesive Laryngoscope 95:1074 1076 (Sep. 1985). * |
K. K. Jain "Repair of small blood vessels with the neodyomium yag laser" Surgery vol. 85 No. 6 pp. 684-688 (1979) (no month avail.). |
K. K. Jain Repair of small blood vessels with the neodyomium yag laser Surgery vol. 85 No. 6 pp. 684 688 (1979) (no month avail.). * |
Khalid J. Awan et al "use of Isobutyl -2- Cyanoacrylate tissue adhesive" Annals of Opth pp. 851-853 (Aug. 1974). |
Khalid J. Awan et al use of Isobutyl 2 Cyanoacrylate tissue adhesive Annals of Opth pp. 851 853 (Aug. 1974). * |
L. S. Bass et al "Sutureless Microvascular Anastomosis using the Yag Laser---" Microsurgery 10:189-193 (1989) (no month avail.). |
L. S. Bass et al Sutureless Microvascular Anastomosis using the Yag Laser Microsurgery 10:189 193 (1989) (no month avail.). * |
L. W. Murray et al "Cross-linking of extra cellular matrix Proteins---" Lasers in Surg. ± Med. 9:490-496 (1989) (no month avail.). |
L. W. Murray et al Cross linking of extra cellular matrix Proteins Lasers in Surg. Med. 9:490 496 (1989) (no month avail.). * |
M. C. Oz et al "Tissue soldering by use of indocyanine green---" J. Vasc. Surg. 718-725 11:5 (May 1990) (no month avail.). |
M. C. Oz et al Tissue soldering by use of indocyanine green J. Vasc. Surg. 718 725 11:5 (May 1990) (no month avail.). * |
M. P. Fried et al "Head ± Neck applications of the milliwat Laser" Lasers in surg ± Med. 7:46-50 (1987) (no month avail.). |
M. P. Fried et al Head Neck applications of the milliwat Laser Lasers in surg Med. 7:46 50 (1987) (no month avail.). * |
P. T. O. Gilbert et al "Laser-Assisted Vasovasotomy" Lasers in Surg. ± Med. 9:42-44 (1989) (no month avail.). |
P. T. O. Gilbert et al Laser Assisted Vasovasotomy Lasers in Surg. Med. 9:42 44 (1989) (no month avail.). * |
R. A. White et al "Mechanism of Tissue Fusion in Argon Laser-welded---" Lasers in Surg ± Med 8:83-89 (1988) (no month avail.). |
R. A. White et al Mechanism of Tissue Fusion in Argon Laser welded Lasers in Surg Med 8:83 89 (1988) (no month avail.). * |
R. L. Burleson et al "Fibrin Adherence to biologic tissues" J. Surg. Research 25,523-529 (1978) (no month avail.). |
R. L. Burleson et al Fibrin Adherence to biologic tissues J. Surg. Research 25,523 529 (1978) (no month avail.). * |
R. Moosdorf et al "Laser-Assisted Anastomosis of the Trachea---" V. Surg. pp. 51-58 (Jan./Feb. 1989). |
R. Moosdorf et al Laser Assisted Anastomosis of the Trachea V. Surg. pp. 51 58 (Jan./Feb. 1989). * |
R. R. Krueger et al "Argon Laser Coagulation of Blood for the Anastomosis of small vessels" Laser in Surg. ±Med 5:55-60 1985 (no month available). |
R. R. Krueger et al Argon Laser Coagulation of Blood for the Anastomosis of small vessels Laser in Surg. Med 5:55 60 1985 (no month available). * |
S. R. Gundry et al "A quantitative and Qualitative comparison of Fibrin Glue Albumin---" J. Surg. Res. 43:75-77 (1987) (no month avail.). |
S. R. Gundry et al A quantitative and Qualitative comparison of Fibrin Glue Albumin J. Surg. Res. 43:75 77 (1987) (no month avail.). * |
S. Rochkind et al "Low-Energy Co2 Laser Intestinal Anastomosis---" Laser in Surg ± Med 8:579-583 (1988) (no month avail.). |
S. Rochkind et al Low Energy Co2 Laser Intestinal Anastomosis Laser in Surg Med 8:579 583 (1988) (no month avail.). * |
Su Wang et al "Effect of blood bonding on Bursting Strength---" Microsurgery 9:10-13 (1988) (no month avail.). |
Su Wang et al Effect of blood bonding on Bursting Strength Microsurgery 9:10 13 (1988) (no month avail.). * |
T. E. Emerson "Unique Features of Albumin; A brief review" Crit. Care Med. vol. 17 No. 7 :690-693 (1989) (no month avail.). |
T. E. Emerson Unique Features of Albumin; A brief review Crit. Care Med. vol. 17 No. 7 :690 693 (1989) (no month avail.). * |
T. T. Liesegang et al "The use of Hydroxypropyl Methyl-Cellulose . . . " Am. J. of Opth. 102:723-726 (Dec. 1986). |
T. T. Liesegang et al The use of Hydroxypropyl Methyl Cellulose . . . Am. J. of Opth. 102:723 726 (Dec. 1986). * |
Cited By (478)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5874537A (en) * | 1991-01-29 | 1999-02-23 | C. R. Bard, Inc. | Method for sealing tissues with collagen-based sealants |
US5669934A (en) * | 1991-02-13 | 1997-09-23 | Fusion Medical Technologies, Inc. | Methods for joining tissue by applying radiofrequency energy to performed collagen films and sheets |
US5824015A (en) * | 1991-02-13 | 1998-10-20 | Fusion Medical Technologies, Inc. | Method for welding biological tissue |
US5994325A (en) * | 1991-05-31 | 1999-11-30 | Gliatech Inc. | Methods and compositions based on inhibition of cell invasion and fibrosis by anionic polymers |
US6020326A (en) * | 1991-05-31 | 2000-02-01 | Gliatech Inc. | Method for inhibition of bone growth by anionic polymers |
US6083930A (en) * | 1991-05-31 | 2000-07-04 | Gliatech Inc. | Methods and compositions based on inhibition of cell invasion and fibrosis by anionic polymers |
US5758663A (en) * | 1992-04-10 | 1998-06-02 | Wilk; Peter J. | Coronary artery by-pass method |
US5716675A (en) | 1992-11-25 | 1998-02-10 | E. Khashoggi Industries | Methods for treating the surface of starch-based articles with glycerin |
US5612050A (en) * | 1993-03-23 | 1997-03-18 | Focal, Inc. | Apparatus and method for local application of polymeric material to tissue |
US5662712A (en) * | 1993-04-28 | 1997-09-02 | Focal, Inc. | Apparatus for intraluminal photothermoforming |
US6176871B1 (en) | 1993-04-28 | 2001-01-23 | Focal, Inc. | Apparatus and methods for intraluminal photothermoforming |
US5849035A (en) * | 1993-04-28 | 1998-12-15 | Focal, Inc. | Methods for intraluminal photothermoforming |
US5741323A (en) * | 1993-04-28 | 1998-04-21 | Focal, Inc. | Polymeric article for intraluminal photothermoforming |
US5843544A (en) | 1994-02-07 | 1998-12-01 | E. Khashoggi Industries | Articles which include a hinged starch-bound cellular matrix |
US5705203A (en) | 1994-02-07 | 1998-01-06 | E. Khashoggi Industries | Systems for molding articles which include a hinged starch-bound cellular matrix |
US5776388A (en) | 1994-02-07 | 1998-07-07 | E. Khashoggi Industries, Llc | Methods for molding articles which include a hinged starch-bound cellular matrix |
US6551618B2 (en) | 1994-03-15 | 2003-04-22 | University Of Birmingham | Compositions and methods for delivery of agents for neuronal regeneration and survival |
US20080152689A1 (en) * | 1994-03-15 | 2008-06-26 | Tissue Repair Company | Devices containing dna encoding neurotrophic agents and related compositions and methods |
US20040138155A1 (en) * | 1994-03-15 | 2004-07-15 | Selective Genetics, Inc. | Devices containing DNA encoding neurotrophic agents and related compositions and methods |
US6060463A (en) * | 1994-04-04 | 2000-05-09 | William Freeman | Treatment of conditions of abnormally increased intraocular pressure by administration of phosphonylmethoxyalkyl nucleoside analogs and related nucleoside analogs |
US5869468A (en) * | 1994-04-04 | 1999-02-09 | Freeman; William R. | Treatment of conditions of abnormally increased intraocular pressure by administration of phosphonylmethoxyalkyl nucleoside analogs and related nucleoside analogs |
US6190691B1 (en) | 1994-04-12 | 2001-02-20 | Adolor Corporation | Methods for treating inflammatory conditions |
US5962477A (en) * | 1994-04-12 | 1999-10-05 | Adolor Corporation | Screening methods for cytokine inhibitors |
US6083902A (en) * | 1994-05-02 | 2000-07-04 | Bristol-Myers Squibb Company | Recombinant fibrin chains, fibrin and fibrin-homologs |
US5665063A (en) * | 1994-06-24 | 1997-09-09 | Focal, Inc. | Methods for application of intraluminal photopolymerized gels |
USRE38158E1 (en) | 1994-07-27 | 2003-06-24 | Minnesota Mining And Manufacturing Company | Adhesive sealant composition |
USRE38827E1 (en) | 1994-07-27 | 2005-10-11 | 3M Innovative Properties Company | Adhesive sealant composition |
US5660873A (en) * | 1994-09-09 | 1997-08-26 | Bioseal, Limited Liability Corporaton | Coating intraluminal stents |
US5990379A (en) * | 1994-11-15 | 1999-11-23 | Kenton W. Gregory & Sisters Of Providence | Prosthetic devices including elastin or elastin-based materials |
US6087552A (en) * | 1994-11-15 | 2000-07-11 | Sisters Of Providence Of Oregon | Method of producing fused biomaterials and tissue |
US6372228B1 (en) | 1994-11-15 | 2002-04-16 | Kenton W. Gregory | Method of producing elastin, elastin-based biomaterials and tropoelastin materials |
US7001328B1 (en) * | 1994-11-15 | 2006-02-21 | Kenton W. Gregory | Method for using tropoelastin and for producing tropoelastin biomaterials |
US20070005148A1 (en) * | 1994-11-15 | 2007-01-04 | Barofsky Andrew D | Method for using tropoelastin and for producing tropoelastin biomaterials |
EP0792125A4 (en) * | 1994-11-15 | 1998-12-30 | Sisters Of Providence In Orego | Elastin, and elastin-based biomaterials and process |
EP0792125A1 (en) * | 1994-11-15 | 1997-09-03 | Sisters Of Providence In Oregon | Elastin, and elastin-based biomaterials and process |
US5989244A (en) * | 1994-11-15 | 1999-11-23 | Gregory; Kenton W. | Method of use of a sheet of elastin or elastin-based material |
US6074663A (en) * | 1995-01-16 | 2000-06-13 | Baxter International Inc. | Method of using cross-linked fibrin material |
US6211335B1 (en) * | 1995-01-20 | 2001-04-03 | The Microsearch Foundation Of Australia | Method of tissue repair |
US20050079997A1 (en) * | 1995-01-20 | 2005-04-14 | Owen Earl Ronald | Method of tissue repair |
US6583117B2 (en) | 1995-01-20 | 2003-06-24 | The Microsearch Foundation Of Australia | Method of tissue repair |
WO1996023039A1 (en) * | 1995-01-23 | 1996-08-01 | The Regents Of The University Of California | Plasma and polymer containing surgical hemostatic adhesives |
US5510102A (en) * | 1995-01-23 | 1996-04-23 | The Regents Of The University Of California | Plasma and polymer containing surgical hemostatic adhesives |
US5773033A (en) * | 1995-01-23 | 1998-06-30 | The Regents Of The University Of California | Fibrinogen/chitosan hemostatic agents |
US6239190B1 (en) * | 1995-01-27 | 2001-05-29 | Tissuemed Limited | Enhancement of activation for ‘biological’ tissue adhesives, bonding agents and sealants using “color change” chromophores |
USRE38730E1 (en) * | 1995-05-05 | 2005-04-26 | Harvest Technologies Corporation | Automatic multiple-decanting centrifuge and method of treating physiological fluids |
US20090028813A1 (en) * | 1995-05-05 | 2009-01-29 | Protein Polymer Technologies, Inc. | Methods for Treating Body Tissue |
US6033654A (en) * | 1995-05-05 | 2000-03-07 | Protein Polymer Technolgies, Inc. | Bonding together tissue with adhesive containing polyfunctional crosslinking agent and protein polymer |
US5895346A (en) * | 1995-05-05 | 1999-04-20 | Wells; John R. | Automatic multiple-decanting centrifuge |
US6423333B1 (en) | 1995-05-05 | 2002-07-23 | Protein Polymer Technologies, Inc. | Sealing or filling tissue defects using polyfunctional crosslinking agents and protein polymers |
US7300663B2 (en) | 1995-05-05 | 2007-11-27 | Protein Polymer Technologies, Inc. | Adhesion and sealing of tissue with compositions containing polyfunctional crosslinking agents and protein polymers |
US20060029638A1 (en) * | 1995-05-05 | 2006-02-09 | Stedronsky Erwin R | Methods for treating body tissue |
US5817303A (en) * | 1995-05-05 | 1998-10-06 | Protein Polymer Technologies, Inc. | Bonding together tissue with adhesive containing polyfunctional crosslinking agent and protein polymer |
US20090023648A1 (en) * | 1995-05-05 | 2009-01-22 | Protein Polymer Technologies, Inc. | Methods for Treating Body Tissue |
USRE38757E1 (en) * | 1995-05-05 | 2005-07-12 | Harvest Technologies Corporation | Automatic multiple-decanting centrifuge and container therefor |
US20030104589A1 (en) * | 1995-05-05 | 2003-06-05 | Protein Polymer Technologies | Tissue adhesive using synthetic crosslinking |
US5707331A (en) * | 1995-05-05 | 1998-01-13 | John R. Wells | Automatic multiple-decanting centrifuge |
WO1996038093A3 (en) * | 1995-06-02 | 1997-03-06 | Childrens Medical Center | Method for laser mediated tissue welding with enhanced strength |
WO1996038093A2 (en) * | 1995-06-02 | 1996-12-05 | Children's Medical Center Corporation | Method for laser mediated tissue welding with enhanced strength |
EP0832095A1 (en) * | 1995-06-07 | 1998-04-01 | Cedars-Sinai Medical Center | A method of cross-linking amino acid-containing polymers using photoactivatable chemical cross-linkers |
EP0832095A4 (en) * | 1995-06-07 | 1999-07-21 | Cedars Sinai Medical Center | A method of cross-linking amino acid-containing polymers using photoactivatable chemical cross-linkers |
WO1996041864A1 (en) * | 1995-06-13 | 1996-12-27 | The Regents Of The University Of California | Diode laser heated micro-reaction chamber with sample detection means |
US5779673A (en) * | 1995-06-26 | 1998-07-14 | Focal, Inc. | Devices and methods for application of intraluminal photopolymerized gels |
US7504386B2 (en) | 1995-08-29 | 2009-03-17 | Fidia Advanced Biopolymers, S.R.L | Biomaterials for preventing post-surgical adhesions comprised of hyaluronic acid derivatives |
US20040192643A1 (en) * | 1995-08-29 | 2004-09-30 | Fidia Advanced Biopolymers, S.R.L. | Biomaterials for preventing post-surgical adhesions comprised of hyaluronic acid derivatives |
US5849761A (en) * | 1995-09-12 | 1998-12-15 | Regents Of The University Of California | Peripherally active anti-hyperalgesic opiates |
US6573282B1 (en) | 1995-09-12 | 2003-06-03 | Adolor Corporation | Peripherally active anti-hyperalgesic opiates |
US6166039A (en) * | 1995-09-12 | 2000-12-26 | Regents Of The Univ. Of California | Peripherally active anti-hyperalgesic opiates |
US6576650B1 (en) | 1995-09-12 | 2003-06-10 | Regents Of The University Of California | Peripherally active anti-hyperalgesic opiates |
US5994372A (en) * | 1995-09-12 | 1999-11-30 | Regents Of The University Of California | Peripherally active anti-hyperalgesic opiates |
US6461325B1 (en) | 1996-01-16 | 2002-10-08 | Baxter International Inc. | Fibrin delivery device and method for forming fibrin on a surface |
US20030202956A1 (en) * | 1996-02-29 | 2003-10-30 | Closure Medical Corporation | Monomeric compositions effective as wound closure devices |
US5935094A (en) * | 1996-05-03 | 1999-08-10 | Uros Corporation And The Regents Of The University Of California | Pentosanpolysulfate coating for medical devices |
US8357378B2 (en) | 1996-08-27 | 2013-01-22 | Baxter International Inc. | Fragmented polymeric compositions and methods for their use |
US8303981B2 (en) | 1996-08-27 | 2012-11-06 | Baxter International Inc. | Fragmented polymeric compositions and methods for their use |
US8512729B2 (en) | 1996-08-27 | 2013-08-20 | Baxter International Inc. | Fragmented polymeric compositions and methods for their use |
US8603511B2 (en) | 1996-08-27 | 2013-12-10 | Baxter International, Inc. | Fragmented polymeric compositions and methods for their use |
US7320962B2 (en) | 1996-08-27 | 2008-01-22 | Baxter International Inc. | Hemoactive compositions and methods for their manufacture and use |
US7871637B2 (en) | 1996-08-27 | 2011-01-18 | Baxter International Inc. | Dry hemostatic compositions and methods for their preparation |
US8557535B2 (en) | 1996-09-23 | 2013-10-15 | Incept Llc | Methods for preparation of platelet rich plasma |
US7592418B2 (en) | 1996-09-23 | 2009-09-22 | Incept Llc | Biocompatible crosslinked polymers with visualization agents |
US20070197776A1 (en) * | 1996-09-23 | 2007-08-23 | Incept Llc | Hydrogels for protein concentration |
US20100069613A1 (en) * | 1996-09-23 | 2010-03-18 | Incept Llc | Implantable materials and compositions |
US7332566B2 (en) | 1996-09-23 | 2008-02-19 | Incept Llc | Biocompatible crosslinked polymers with visualization agents |
US20060147409A1 (en) * | 1996-09-23 | 2006-07-06 | Incept Llc | Biocompatible crosslinked polymers with visualization agents |
US20080214695A1 (en) * | 1996-09-23 | 2008-09-04 | Pathak Chandrashekhar P | Biocompatible crosslinked polymers with visualization agents |
US20080260802A1 (en) * | 1996-09-23 | 2008-10-23 | Sawhney Amarpreet S | Biocompatible hydrogels made with small molecule precursors |
US20090324721A1 (en) * | 1996-09-23 | 2009-12-31 | Jack Kennedy | Hydrogels Suitable For Use In Polyp Removal |
US8003705B2 (en) | 1996-09-23 | 2011-08-23 | Incept Llc | Biocompatible hydrogels made with small molecule precursors |
US7211651B2 (en) * | 1996-09-23 | 2007-05-01 | Incept Llc | Proteinaceous gels having visualization agents and methods of use thereof |
US7605232B2 (en) | 1996-09-23 | 2009-10-20 | Incept Llc | Hydrogels for protein concentration |
US20030077272A1 (en) * | 1996-09-23 | 2003-04-24 | Incept Llc | Proteinaceous gels having visualization agents and methods of use thereof |
EP0862468B2 (en) † | 1996-10-07 | 2008-07-23 | Imedex Biomateriaux | Adhesive composition with macromolecular polyaldehyde base and method for cross-linking collagen |
EP1018983A4 (en) * | 1997-02-07 | 2006-09-27 | Providence Health Sys Oregon | Method of producing biomaterials |
EP1018983A1 (en) * | 1997-02-07 | 2000-07-19 | Sisters Of Providence In Oregon | Method of producing biomaterials |
US20040216181A1 (en) * | 1997-02-19 | 2004-10-28 | Sheng-Zhi Pang | Dna construct to confer multiple traits on plants |
US20050150005A1 (en) * | 1997-02-19 | 2005-07-07 | Sheng-Zhi Pang | DNA construct to confer multiple traits on plants |
US6903248B2 (en) | 1997-02-19 | 2005-06-07 | Cornell Research Foundation, Inc. | DNA constructs and methods to impart resistance to at least one virus on plants |
US7285580B2 (en) * | 1997-06-20 | 2007-10-23 | Protein Polymer Technologies, Inc. | Methods of using primer molecules for enhancing the mechanical performance of tissue adhesives and sealants |
US6258872B1 (en) * | 1997-06-20 | 2001-07-10 | Protein Polymer Technologies, Inc. | Methods of using primer molecules for enhancing the mechanical performance of tissue adhesives and sealants |
US6875796B2 (en) | 1997-06-20 | 2005-04-05 | Protein Polymer Technologies, Inc. | Methods of using primer molecules for enhancing the mechanical performance of tissue adhesives and sealants |
US20030199606A1 (en) * | 1997-06-20 | 2003-10-23 | Stedronsky Erwin R. | Methods of using primer molecules for enhancing the mechanical performance of tissue adhesives and sealants |
US20050129745A1 (en) * | 1997-06-20 | 2005-06-16 | Protein Polymer Technologies, Inc. | Methods of using primer molecules for enhancing the mechanical performance of tissue adhesives and sealants |
US6576685B2 (en) * | 1997-06-20 | 2003-06-10 | Protein Polymer Technologies, Inc. | Methods of using primer molecules for enhancing the mechanical performance of tissue adhesives and sealants |
US5929044A (en) * | 1997-08-14 | 1999-07-27 | Cornell Research Foundation | Protein solder composition and method of use |
US6129928A (en) * | 1997-09-05 | 2000-10-10 | Icet, Inc. | Biomimetic calcium phosphate implant coatings and methods for making the same |
US6113636A (en) * | 1997-11-20 | 2000-09-05 | St. Jude Medical, Inc. | Medical article with adhered antimicrobial metal |
GB2336207B (en) * | 1997-12-24 | 2000-01-12 | Kalibrant Limited | A composition for use in fluorescence assay systems |
GB2336207A (en) * | 1997-12-24 | 1999-10-13 | Kalibrant Limited | A composition for use in fluorescence assay systems |
US6271039B1 (en) | 1997-12-24 | 2001-08-07 | Kalibrant Limited | Composition for use in fluorescence assay systems |
WO1999034219A1 (en) * | 1997-12-24 | 1999-07-08 | Kalibrant Limited | A composition for use in fluorescence assay systems |
US6724958B1 (en) | 1998-01-23 | 2004-04-20 | Science & Engineering Associates, Inc. | Handheld laser system emitting visible non-visible radiation |
US6600142B2 (en) | 1998-03-17 | 2003-07-29 | Codaco, Inc. | RF active compositions for use in adhesion, bonding and coating |
US6348679B1 (en) | 1998-03-17 | 2002-02-19 | Ameritherm, Inc. | RF active compositions for use in adhesion, bonding and coating |
WO1999051282A1 (en) * | 1998-04-06 | 1999-10-14 | Cornell Research Foundation, Inc. | Composition for tissue welding and method of use |
US6323037B1 (en) * | 1998-04-06 | 2001-11-27 | Cornell Research Foundation, Inc. | Composition for tissue welding and method of use |
EP0956869A2 (en) * | 1998-05-15 | 1999-11-17 | Hogy Medical Co., Ltd. | Tissue sealant |
EP0956869A3 (en) * | 1998-05-15 | 2001-08-22 | Hogy Medical Co., Ltd. | Tissue sealant |
EP1082126A4 (en) * | 1998-05-27 | 2003-04-02 | Hadasit Med Res Service | Novel peptides |
US7122620B1 (en) | 1998-05-27 | 2006-10-17 | Medical Research Services And Development Ltd. | Haptotactic peptides |
EP1082126A1 (en) * | 1998-05-27 | 2001-03-14 | Hadasit Medical Research Services & Development Co. Ltd. | Novel peptides |
US20070009571A1 (en) * | 1998-05-27 | 2007-01-11 | Hadasit Medical Research Services & Development Ltd. | Novel haptotactic peptides |
US20050079999A1 (en) * | 1998-06-23 | 2005-04-14 | James Wilkie | Methods for controlling the viscosity of polymer-based tissue sealants and adhesives |
US20040072756A1 (en) * | 1998-06-23 | 2004-04-15 | James Wilkie | Primers for use with tissue sealants and adhesives and methods for using the same |
US20050037960A1 (en) * | 1998-06-23 | 2005-02-17 | James Rolke | Methods and compositions for sealing tissue leaks |
US20040063613A1 (en) * | 1998-06-23 | 2004-04-01 | James Rolke | Methods and compositions for sealing tissue leaks |
US6585773B1 (en) | 1998-08-21 | 2003-07-01 | Providence Health System-Oregon | Insertable stent and methods of making and using same |
US20050019264A1 (en) * | 1998-11-02 | 2005-01-27 | Xantech Pharmaceuticals, Inc. | Ultrasound contrast using halogenated xanthenes |
US7226657B1 (en) | 1998-11-04 | 2007-06-05 | Baxter International Inc. | Element provided with a fibrin layer, preparation and use thereof |
US20020115066A1 (en) * | 1998-11-26 | 2002-08-22 | Hope Ralph Graham | Viral therapeutics |
US8535705B2 (en) | 1998-12-04 | 2013-09-17 | Incept, Llc | Biocompatible polymers and hydrogels and methods of use |
US20080095736A1 (en) * | 1998-12-04 | 2008-04-24 | Incept Llc | Biocompatible polymers and hydrogels and methods of use |
WO2000040277A1 (en) * | 1999-01-08 | 2000-07-13 | Browdie David A | Tissue adhesive for treating vigorously bleeding surfaces |
US6310036B1 (en) * | 1999-01-09 | 2001-10-30 | Last Chance Tissue Adhesives Corporation | High strength, Bio-compatible tissue adhesive and methods for treating vigorously bleeding surfaces |
US20080038352A1 (en) * | 1999-02-25 | 2008-02-14 | Virginia Commonwealth University Intellectual Property Foundation | Electroprocessed Collagen and Tissue Engineering |
US7759082B2 (en) | 1999-02-25 | 2010-07-20 | Virginia Commonwealth University Intellectual Property Foundation | Electroprocessed fibrin-based matrices and tissues |
US20100310658A1 (en) * | 1999-02-25 | 2010-12-09 | Bowlin Gary L | Electroprocessed Fibrin-Based Matrices and Tissues |
US20040229333A1 (en) * | 1999-02-25 | 2004-11-18 | Bowlin Gary L. | Electroprocessed fibrin-based matrices and tissues |
US20040116032A1 (en) * | 1999-02-25 | 2004-06-17 | Bowlin Gary L. | Electroprocessed collagen |
US7615373B2 (en) | 1999-02-25 | 2009-11-10 | Virginia Commonwealth University Intellectual Property Foundation | Electroprocessed collagen and tissue engineering |
US20040018226A1 (en) * | 1999-02-25 | 2004-01-29 | Wnek Gary E. | Electroprocessing of materials useful in drug delivery and cell encapsulation |
US20040037813A1 (en) * | 1999-02-25 | 2004-02-26 | Simpson David G. | Electroprocessed collagen and tissue engineering |
US8226708B1 (en) * | 1999-03-03 | 2012-07-24 | Trivascular, Inc. | Inflatable intraluminal graft |
US6398972B1 (en) | 1999-04-12 | 2002-06-04 | Harvest Technologies Corporation | Method for producing platelet rich plasma and/or platelet concentrate |
WO2000062827A2 (en) * | 1999-04-16 | 2000-10-26 | Cohesion Technologies, Inc. | Rapid gelling biocompatible polymer composition |
WO2000062827A3 (en) * | 1999-04-16 | 2001-01-18 | Cohesion Tech Inc | Rapid gelling biocompatible polymer composition |
US6312725B1 (en) | 1999-04-16 | 2001-11-06 | Cohesion Technologies, Inc. | Rapid gelling biocompatible polymer composition |
US6624245B2 (en) | 1999-04-16 | 2003-09-23 | Cohesion Technologies, Inc. | Rapid-gelling biocompatible polymer composition and associated methods of preparation and use |
US7138441B1 (en) | 1999-05-29 | 2006-11-21 | United States Surgical Corporation | Bioabsorbable blends and surgical articles therefrom |
US6706690B2 (en) | 1999-06-10 | 2004-03-16 | Baxter Healthcare Corporation | Hemoactive compositions and methods for their manufacture and use |
US20050049178A1 (en) * | 1999-07-06 | 2005-03-03 | Oberschwabenklinik Gmbh | Agent for the occlusion of blood vessels |
US7374774B2 (en) | 1999-08-31 | 2008-05-20 | Virginia Commonwealth University Intellectual Property Foundation | Electroprocessed material made by simultaneously electroprocessing a natural protein polymer and two synthetic polymers |
US20080159985A1 (en) * | 1999-08-31 | 2008-07-03 | Virginia Commonwealth University Intellectual Property Foundation | Electroprocessing in drug delivery and cell encapsulation |
US20040058887A1 (en) * | 1999-08-31 | 2004-03-25 | Bowlin Gary L. | Electroprocessing in drug delivery and cell encapsulation |
WO2001017571A1 (en) * | 1999-09-03 | 2001-03-15 | Sulzer Vascutek Limited | Sealant for vascular prostheses |
US6351663B1 (en) | 1999-09-10 | 2002-02-26 | Akorn, Inc. | Methods for diagnosing and treating conditions associated with abnormal vasculature using fluorescent dye angiography and dye-enhanced photocoagulation |
US20030060718A1 (en) * | 1999-09-10 | 2003-03-27 | Akorn, Inc. | Indocyanine green (ICG) compositions and related methods of use |
US6944493B2 (en) | 1999-09-10 | 2005-09-13 | Akora, Inc. | Indocyanine green (ICG) compositions and related methods of use |
US6849092B2 (en) | 1999-09-13 | 2005-02-01 | Keraplast Technologies, Ltd. | Implantable prosthetic or tissue expanding device |
US6783546B2 (en) | 1999-09-13 | 2004-08-31 | Keraplast Technologies, Ltd. | Implantable prosthetic or tissue expanding device |
US20050169963A1 (en) * | 1999-09-13 | 2005-08-04 | Southwest Ressearch Institute | Implantable prosthetic or tissue expanding device |
US6183498B1 (en) | 1999-09-20 | 2001-02-06 | Devore Dale P. | Methods and products for sealing a fluid leak in a tissue |
US6649888B2 (en) | 1999-09-23 | 2003-11-18 | Codaco, Inc. | Radio frequency (RF) heating system |
US6391049B1 (en) | 1999-10-06 | 2002-05-21 | Board Of Regents The University Of Texas System | Solid biodegradable device for use in tissue repair |
USRE43134E1 (en) | 1999-10-08 | 2012-01-24 | Providence Health System - Oregon | Biocompatible denatured albumin lamina |
US6680063B1 (en) | 1999-10-08 | 2004-01-20 | Providence Health System-Oregon | Biocompatible albumin lamina and method |
WO2001026624A1 (en) * | 1999-10-08 | 2001-04-19 | Providence Health System - Oregon | Biocompatible albumin lamina and method |
WO2001030405A1 (en) * | 1999-10-28 | 2001-05-03 | Tissuemed Ltd. | Flexible sheets for use in therapy |
US6443976B1 (en) | 1999-11-30 | 2002-09-03 | Akorn, Inc. | Methods for treating conditions and illnesses associated with abnormal vasculature |
US20040215231A1 (en) * | 2000-02-03 | 2004-10-28 | David Fortune | Device for the closure of a surgical puncture |
US6808707B2 (en) | 2000-02-04 | 2004-10-26 | Matrix Design | Wound healing compositions and methods using tropoelastin and lysyl oxidase |
US20050175600A1 (en) * | 2000-02-04 | 2005-08-11 | Ensley Burt D. | Wound healing compositions and methods using tropoelastin and lysyl oxidase |
US20080038243A1 (en) * | 2000-02-04 | 2008-02-14 | Matrix Design | Wound healing compositions and methods using tropoelastin and lysyl oxidase |
WO2001058452A1 (en) * | 2000-02-08 | 2001-08-16 | Tissuemed Limited | Thermal ablation of tissue |
US8092490B2 (en) | 2000-02-11 | 2012-01-10 | The General Hospital Corporation | Photochemical tissue bonding |
US20050038471A1 (en) * | 2000-02-11 | 2005-02-17 | Barbara Chan | Photochemical tissue bonding |
US7073510B2 (en) | 2000-02-11 | 2006-07-11 | The General Hospital Corporation | Photochemical tissue bonding |
US20080009901A1 (en) * | 2000-02-11 | 2008-01-10 | Redmond Robert W | Photochemical tissue bonding |
US7331350B2 (en) | 2000-02-11 | 2008-02-19 | The General Hospital Corporation | Photochemical tissue bonding |
EP1272119A4 (en) * | 2000-02-11 | 2005-09-14 | Gen Hospital Corp | Photochemical tissue bonding |
US20060212070A1 (en) * | 2000-02-11 | 2006-09-21 | Redmond Robert W | Photochemical tissue bonding |
US20020187935A1 (en) * | 2000-02-11 | 2002-12-12 | Redmond Robert W. | Photochemical tissue bonding |
US8215314B2 (en) * | 2000-02-11 | 2012-07-10 | The General Hospital Corporation | Photochemical tissue bonding |
US7351422B2 (en) | 2000-02-22 | 2008-04-01 | Hogy Medical Co., Ltd. | Hemostatic soluble cellulose fibers containing coagulating protein for treating wound and process for producing the same |
US20030216718A1 (en) * | 2000-03-16 | 2003-11-20 | Hamblin Michael R. | Methods for tissue welding using laser-activated protein solders |
US7077839B2 (en) | 2000-03-16 | 2006-07-18 | General Hospital Corporation | Methods for tissue welding using laser-activated protein solders |
US6607522B1 (en) | 2000-03-16 | 2003-08-19 | General Hospital Corporation | Methods for tissue welding using laser-activated protein solders |
DE10015145A1 (en) * | 2000-03-29 | 2001-10-11 | Fraunhofer Ges Forschung | Connector for vessel anastomosis comprises mesh metal inner sleeve covered by biocompatible biodegradable polymer outer sleeve to clamp vessel ends after laser shrinkage with retained flow section. |
US7727547B2 (en) | 2000-04-04 | 2010-06-01 | Tissuemed Limited | Tissue-adhesive formulations |
US6682760B2 (en) | 2000-04-18 | 2004-01-27 | Colbar R&D Ltd. | Cross-linked collagen matrices and methods for their preparation |
US20030124190A1 (en) * | 2000-06-26 | 2003-07-03 | Epicept, Inc. | Methods and compositions for treating pain of the mucous membrane |
US6509028B2 (en) | 2000-06-26 | 2003-01-21 | Epicept Corporation | Methods and compositions for treating pain of the mucous membrane |
US6787357B2 (en) | 2000-09-01 | 2004-09-07 | Virginia Commonwealth University | Plasma-derived fibrin-based matrices and tissue |
WO2002024159A2 (en) | 2000-09-22 | 2002-03-28 | Durect Corporation | Implantable drug delivery patch |
US20040049187A1 (en) * | 2000-10-23 | 2004-03-11 | Stuart Burnett | Self-adhesive hydratable matrix for topical therapeutic use |
US20140243675A1 (en) * | 2000-11-20 | 2014-08-28 | Senorx, Inc. | Tissue site markers for in vivo imaging |
EP2080520A1 (en) | 2001-02-23 | 2009-07-22 | The Scripps Research Institute | Tryptophanyl-tRNA synthetase derived polypeptides useful for the regulation of angiogenesis |
US9345460B2 (en) | 2001-04-24 | 2016-05-24 | Cardiovascular Technologies, Inc. | Tissue closure devices, device and systems for delivery, kits and methods therefor |
US7025776B1 (en) | 2001-04-24 | 2006-04-11 | Advanced Catheter Engineering, Inc. | Arteriotomy closure devices and techniques |
US8518063B2 (en) | 2001-04-24 | 2013-08-27 | Russell A. Houser | Arteriotomy closure devices and techniques |
US7122720B2 (en) | 2001-04-24 | 2006-10-17 | Cornell Research Foundation, Inc. | Synthetic nucleic acid molecule for imparting multiple traits |
US8992567B1 (en) | 2001-04-24 | 2015-03-31 | Cardiovascular Technologies Inc. | Compressible, deformable, or deflectable tissue closure devices and method of manufacture |
US20030190700A1 (en) * | 2001-04-24 | 2003-10-09 | Dennis Gonsalves | Synthetic nucleic acid molecule for imparting multiple traits |
US7534938B2 (en) | 2001-04-24 | 2009-05-19 | Cornell Research Foundation, Inc. | Synthetic nucleic acid molecule for imparting multiple traits |
US20030003157A1 (en) * | 2001-06-06 | 2003-01-02 | University Of Medicine & Dentistry Of New Jersey | Collagen compositions and methods for making and using the same |
US6623959B2 (en) | 2001-06-13 | 2003-09-23 | Ethicon, Inc. | Devices and methods for cell harvesting |
US20090227779A1 (en) * | 2001-07-17 | 2009-09-10 | Baxter International, Inc. | Dry hemostatic compositions and methods for their preparation |
US8383141B2 (en) | 2001-07-17 | 2013-02-26 | Baxter International Inc. | Dry hemostatic compositions and methods for their preparation |
US20080286376A1 (en) * | 2001-07-17 | 2008-11-20 | Fusion Medical Technologies, Inc. | Dry hemostatic compositions and methods for their preparation |
US8092820B2 (en) | 2001-07-17 | 2012-01-10 | Baxter International Inc. | Dry hemostatic compositions and methods for their preparation |
US20030064088A1 (en) * | 2001-08-29 | 2003-04-03 | Carvalho Ricardo Azevedo Pontes De | Implantable and sealable system for unidirectional delivery of therapeutic agents to tissues |
US7195774B2 (en) * | 2001-08-29 | 2007-03-27 | Carvalho Ricardo Azevedo Ponte | Implantable and sealable system for unidirectional delivery of therapeutic agents to tissues |
US6685730B2 (en) | 2001-09-26 | 2004-02-03 | Rice University | Optically-absorbing nanoparticles for enhanced tissue repair |
US6773699B1 (en) | 2001-10-09 | 2004-08-10 | Tissue Adhesive Technologies, Inc. | Light energized tissue adhesive conformal patch |
US6939364B1 (en) * | 2001-10-09 | 2005-09-06 | Tissue Adhesive Technologies, Inc. | Composite tissue adhesive |
US6780840B1 (en) | 2001-10-09 | 2004-08-24 | Tissue Adhesive Technologies, Inc. | Method for making a light energized tissue adhesive |
US20030185870A1 (en) * | 2001-11-20 | 2003-10-02 | Grinstaff Mark W. | Interfacial biomaterials |
US20050042240A1 (en) * | 2002-01-28 | 2005-02-24 | Utterberg David S. | High viscosity antibacterials |
US20030175323A1 (en) * | 2002-01-28 | 2003-09-18 | Utterberg David S. | High viscosity antibacterials for cannulae |
US20080096977A1 (en) * | 2002-08-06 | 2008-04-24 | Matrix Medical, Llc | Biocompatible phase invertable proteinaceous compositions and methods for making and using the same |
US8349348B2 (en) | 2002-08-06 | 2013-01-08 | Matrix Medical, Llc | Biocompatible phase invertible proteinaceous compositions and methods for making and using the same |
EP3915541A1 (en) | 2002-08-06 | 2021-12-01 | BAXTER INTERNATIONAL INC. (a Delaware corporation) | Biocompatible phase invertible proteinaceous compositions and methods for making and using the same |
EP3915529A1 (en) | 2002-08-06 | 2021-12-01 | BAXTER INTERNATIONAL INC. (a Delaware corporation) | Biocompatible phase invertible proteinaceous compositions and methods for making and using the same |
US10398801B2 (en) | 2002-08-06 | 2019-09-03 | Baxter International Inc. | Biocompatible phase invertable proteinaceous compositions and methods for making and using the same |
EP3417848A1 (en) | 2002-08-06 | 2018-12-26 | Baxter International, Inc. | Biocompatible phase invertable proteinaceous compositions and methods for making and using the same |
US10098981B2 (en) | 2002-08-06 | 2018-10-16 | Baxter International Inc. | Biocompatible phase invertable proteinaceous compositions and methods for making and using the same |
US20100029913A1 (en) * | 2002-08-06 | 2010-02-04 | Kemal Schankereli | Biocompatible phase invertible proteinaceous compositions and methods for making and using the same |
US7303757B2 (en) | 2002-08-06 | 2007-12-04 | Matrix Medical, Llc | Biocompatible phase invertable proteinaceous compositions and methods for making and using the same |
US9101536B2 (en) | 2002-08-06 | 2015-08-11 | Matrix Medical Llc | Biocompatible phase invertable proteinaceous compositions and methods for making and using the same |
US20100144590A1 (en) * | 2002-08-06 | 2010-06-10 | Kemal Schankereli | Biocompatible phase invertable proteinaceous compositions and methods for making and using the same |
US7871639B2 (en) | 2002-08-06 | 2011-01-18 | Matrix Medical, Llc | Biocompatible phase invertable proteinaceous compositions and methods for making and using the same |
US20050073131A1 (en) * | 2002-08-07 | 2005-04-07 | Markus Krumbeck | Combination of ski and ski binding |
US20080109002A1 (en) * | 2002-10-04 | 2008-05-08 | Yves Delmotte | Devices for mixing and extruding medically useful compositions |
US7766919B2 (en) | 2002-10-04 | 2010-08-03 | Baxter International Inc. | Devices for mixing and extruding medically useful compositions |
US20040068266A1 (en) * | 2002-10-04 | 2004-04-08 | Yves Delmotte | Devices and methods for mixing and extruding medically useful compositions |
US7135027B2 (en) | 2002-10-04 | 2006-11-14 | Baxter International, Inc. | Devices and methods for mixing and extruding medically useful compositions |
US20070003480A1 (en) * | 2002-11-03 | 2007-01-04 | Hapto Biotech, Inc. | Liposomal composition comprising haptotactic peptides |
US20040236371A1 (en) * | 2003-01-24 | 2004-11-25 | Mcnally-Heintzelman Karen M. | Light-activated adhesive composite, system, and methods of use thereof |
WO2004067044A3 (en) * | 2003-01-24 | 2004-12-09 | Rose Hulman Inst Of Technology | Light-activated adhesive composite, system, and methods |
WO2004067045A3 (en) * | 2003-01-24 | 2004-11-18 | Rose Hulman Inst Of Technology | Non-light activated adhesive composite, system, and methods |
WO2004067045A2 (en) * | 2003-01-24 | 2004-08-12 | Rose-Hulman Institute Of Technology | Non-light activated adhesive composite, system, and methods |
WO2004067044A2 (en) * | 2003-01-24 | 2004-08-12 | Rose-Hulman Institute Of Technology | Light-activated adhesive composite, system, and methods |
US7501133B2 (en) | 2003-01-24 | 2009-03-10 | Rose-Hulman Institute Of Technology | Light-activated adhesive composite, system, and methods of use thereof |
US20050131401A1 (en) * | 2003-03-27 | 2005-06-16 | Cierra, Inc. | Energy based devices and methods for treatment of anatomic tissue defects |
US8038671B2 (en) | 2003-03-27 | 2011-10-18 | Terumo Kabushiki Kaisha | Energy based devices and methods for treatment of patent foramen ovale |
US20070044811A1 (en) * | 2003-03-27 | 2007-03-01 | Cierra, Inc. | Energy based devices and methods for treatment of patent foramen ovale |
US20050034735A1 (en) * | 2003-03-27 | 2005-02-17 | Cierra, Inc. | Methods and apparatus for treatment of patent foramen ovale |
US20040267191A1 (en) * | 2003-03-27 | 2004-12-30 | Cierra, Inc. | Methods and apparatus for treatment of patent foramen ovale |
US20050080406A1 (en) * | 2003-03-27 | 2005-04-14 | Cierra, Inc. | Energy based devices and methods for treatment of patent foramen ovale |
US8075554B2 (en) | 2003-03-27 | 2011-12-13 | Terumo Kabushiki Kaisha | Energy based devices and methods for treatment of patent foramen ovale |
US8070747B2 (en) | 2003-03-27 | 2011-12-06 | Terumo Kabushiki Kaisha | Energy based devices and methods for treatment of patent foramen ovale |
US20060241584A1 (en) * | 2003-03-27 | 2006-10-26 | Cierra, Inc. | Energy based devices and methods for treatment of patent foramen ovale |
US20060241581A1 (en) * | 2003-03-27 | 2006-10-26 | Cierra, Inc. | Energy based devices and methods for treatment of patent foramen ovale |
US8066701B2 (en) | 2003-03-27 | 2011-11-29 | Terumo Kabushiki Kaisha | Energy based devices and methods for treatment of patent foramen ovale |
US20060241582A1 (en) * | 2003-03-27 | 2006-10-26 | Cierra, Inc. | Energy based devices and methods for treatment of patent foramen ovale |
US8057469B2 (en) | 2003-03-27 | 2011-11-15 | Terumo Kabushiki Kaisha | Methods and apparatus for treatment of patent foramen ovale |
US8052678B2 (en) | 2003-03-27 | 2011-11-08 | Terumo Kabushiki Kaisha | Energy based devices and methods for treatment of patent foramen ovale |
US8038672B2 (en) | 2003-03-27 | 2011-10-18 | Terumo Kabushiki Kaisha | Energy based devices and methods for treatment of patent foramen ovale |
US8038673B2 (en) | 2003-03-27 | 2011-10-18 | Terumo Kabushiki Kaisha | Energy based devices and methods for treatment of patent foramen ovale |
US20050021016A1 (en) * | 2003-03-27 | 2005-01-27 | Cierra, Inc. | Energy based devices and methods for treatment of anatomic tissue defects |
US8038669B2 (en) | 2003-03-27 | 2011-10-18 | Terumo Kabushiki Kaisha | Energy based devices and methods for treatment of patent foramen ovale |
US20070123852A1 (en) * | 2003-03-27 | 2007-05-31 | Cierra, Inc. | Methods and apparatus for closing a layered tissue defect |
US8021362B2 (en) | 2003-03-27 | 2011-09-20 | Terumo Kabushiki Kaisha | Methods and apparatus for closing a layered tissue defect |
US7293562B2 (en) | 2003-03-27 | 2007-11-13 | Cierra, Inc. | Energy based devices and methods for treatment of anatomic tissue defects |
US8465485B2 (en) | 2003-03-27 | 2013-06-18 | Terumo Kabushiki Kaisha | Energy based devices and methods for treatment of patent foramen ovale |
US7186251B2 (en) | 2003-03-27 | 2007-03-06 | Cierra, Inc. | Energy based devices and methods for treatment of patent foramen ovale |
US7972330B2 (en) | 2003-03-27 | 2011-07-05 | Terumo Kabushiki Kaisha | Methods and apparatus for closing a layered tissue defect |
US20070078485A1 (en) * | 2003-03-27 | 2007-04-05 | Cierra, Inc. | Methods and apparatus for treatment of patent foramen ovale |
US7922716B2 (en) | 2003-03-27 | 2011-04-12 | Terumo Kabushiki Kaisha | Energy based devices and methods for treatment of anatomic tissue defects |
US7914527B2 (en) | 2003-03-27 | 2011-03-29 | Terumo Kabushiki Kaisha | Energy based devices and methods for treatment of patent foramen ovale |
US20040230185A1 (en) * | 2003-03-27 | 2004-11-18 | Cierra, Inc. | Energy based devices and methods for treatment of patent foramen ovale |
US20050131460A1 (en) * | 2003-03-27 | 2005-06-16 | Cierra, Inc. | Methods and apparatus for treatment of patent foramen ovale |
US8852181B2 (en) | 2003-03-27 | 2014-10-07 | Terumo Kabushiki Kaisha | Energy based devices and methods for treatment of anatomic tissue defects |
US7165552B2 (en) | 2003-03-27 | 2007-01-23 | Cierra, Inc. | Methods and apparatus for treatment of patent foramen ovale |
US20060276779A1 (en) * | 2003-03-27 | 2006-12-07 | Cierra, Inc. | Energy based devices and methods for treatment of patent foramen ovale |
US20080004658A1 (en) * | 2003-03-27 | 2008-01-03 | Cierra, Inc. | Energy based devices and methods for treatment of anatomic tissue defects |
US7637924B2 (en) | 2003-03-27 | 2009-12-29 | Terumo Kabushiki Kaisha | Methods and apparatus for treatment of patent foramen ovale |
WO2004087227A1 (en) * | 2003-04-04 | 2004-10-14 | Tissuemed Limited | Tissue-adhesive formulations |
US20060105026A1 (en) * | 2003-04-04 | 2006-05-18 | Fortune David H | Tissue-adhesive formulations |
US8834864B2 (en) | 2003-06-05 | 2014-09-16 | Baxter International Inc. | Methods for repairing and regenerating human dura mater |
US20060167561A1 (en) * | 2003-06-05 | 2006-07-27 | Johann Odar | Methods for repairing and regenerating human dura mater |
US20070027445A1 (en) * | 2003-06-10 | 2007-02-01 | Gifford Hanson S | Methods and apparatus for non-invasively treating patent foramen ovale using high intensity focused ultrasound |
US7311701B2 (en) | 2003-06-10 | 2007-12-25 | Cierra, Inc. | Methods and apparatus for non-invasively treating atrial fibrillation using high intensity focused ultrasound |
US20050228283A1 (en) * | 2003-06-10 | 2005-10-13 | Gifford Hanson S | Methods and apparatus for non-invasively treating atrial fibrillation using high intensity focused ultrasound |
US9302125B2 (en) | 2003-06-10 | 2016-04-05 | The Foundry, Llc | Methods and apparatus for non-invasively treating atrial fibrillation using high intensity focused ultrasound |
US20080058683A1 (en) * | 2003-06-10 | 2008-03-06 | Cierra, Inc. | Method and apparatus for non-invasively treating patent foramen ovale using high intensity focused ultrasound |
US20040254521A1 (en) * | 2003-06-16 | 2004-12-16 | Solx, Inc. | Shunt for the treatment of glaucoma |
US7207965B2 (en) | 2003-06-16 | 2007-04-24 | Solx, Inc. | Shunt for the treatment of glaucoma |
US8252747B2 (en) | 2003-07-23 | 2012-08-28 | Johan Lowinger | Tissue adhesive sealant |
US7129210B2 (en) | 2003-07-23 | 2006-10-31 | Covalent Medical, Inc. | Tissue adhesive sealant |
US20090287313A1 (en) * | 2003-07-23 | 2009-11-19 | Johan Lowinger | Tissue adhesive sealant |
US20050069589A1 (en) * | 2003-07-23 | 2005-03-31 | Johan Lowinger | Tissue adhesive sealant |
US20070025955A1 (en) * | 2003-07-23 | 2007-02-01 | Johan Lowinger | Tissue adhesive sealant |
US20100183582A1 (en) * | 2003-08-07 | 2010-07-22 | Ethicon, Inc. | Hemostatic compositions containing sterile thrombin |
WO2005037108A2 (en) * | 2003-10-21 | 2005-04-28 | Ramot At Tel Aviv University Ltd. | Compositions and devices including same useful for anastomosis |
US20070213768A1 (en) * | 2003-10-21 | 2007-09-13 | Irena Wasserman | Compositions and Devices Including Same Useful for Anastomosis |
WO2005037108A3 (en) * | 2003-10-21 | 2006-01-05 | Univ Ramot | Compositions and devices including same useful for anastomosis |
US20050125033A1 (en) * | 2003-12-04 | 2005-06-09 | Mcnally-Heintzelman Karen M. | Wound closure apparatus |
US20050125015A1 (en) * | 2003-12-04 | 2005-06-09 | Mcnally-Heintzelman Karen M. | Tissue-handling apparatus, system and method |
US20050165385A1 (en) * | 2004-01-22 | 2005-07-28 | Solx, Inc. | Glaucoma treatment method |
US7282046B2 (en) | 2004-01-22 | 2007-10-16 | Peter M. Adams, Doug P. Adams, and John Sullivan, Collectively as the Stockholder Representative Committee | Glaucoma treatment method |
US8481073B2 (en) | 2004-04-28 | 2013-07-09 | Angiodevice International Gmbh | Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use |
US8067031B2 (en) | 2004-04-28 | 2011-11-29 | Angiodevice International Gmbh | Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use |
US8460708B2 (en) | 2004-04-28 | 2013-06-11 | Angiodevice International Gmbh | Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use |
US20100137986A1 (en) * | 2004-06-07 | 2010-06-03 | Dfine, Inc. | Implants and methods for treating bone |
US20060089715A1 (en) * | 2004-06-07 | 2006-04-27 | Csaba Truckai | Implants and methods for treating bone |
US7621952B2 (en) | 2004-06-07 | 2009-11-24 | Dfine, Inc. | Implants and methods for treating bone |
US8409289B2 (en) | 2004-06-07 | 2013-04-02 | Dfine, Inc. | Implants and methods for treating bone |
US8163031B2 (en) | 2004-06-09 | 2012-04-24 | Dfine, Inc. | Composites and methods for treating bone |
US20110054482A1 (en) * | 2004-06-09 | 2011-03-03 | Dfine, Inc. | Composites and methods for treating bone |
US8133221B2 (en) | 2004-06-21 | 2012-03-13 | Terumo Kabushiki Kaisha | Energy based devices and methods for treatment of anatomic tissue defects |
US20060074410A1 (en) * | 2004-06-21 | 2006-04-06 | Cierra, Inc. | Energy based devices and methods for treatment of anatomic tissue defects |
US7367975B2 (en) | 2004-06-21 | 2008-05-06 | Cierra, Inc. | Energy based devices and methods for treatment of anatomic tissue defects |
US7766938B2 (en) * | 2004-07-08 | 2010-08-03 | Pneumrx, Inc. | Pleural effusion treatment device, method and material |
US20060009801A1 (en) * | 2004-07-08 | 2006-01-12 | Mcgurk Erin | Pleural effusion treatment device, method and material |
US20060024372A1 (en) * | 2004-07-29 | 2006-02-02 | Utterberg David S | High viscosity antibacterials |
US8133504B2 (en) | 2004-08-03 | 2012-03-13 | Tissuemed Limited | Tissue-adhesive materials |
US20070286891A1 (en) * | 2004-08-03 | 2007-12-13 | Tissuemed Limited | Tissue-Adhesive Materials |
US20060106459A1 (en) * | 2004-08-30 | 2006-05-18 | Csaba Truckai | Bone treatment systems and methods |
US20060094865A1 (en) * | 2004-10-29 | 2006-05-04 | Kapur Terri A | Intraoperative method for isolating and concentrating autologous growth factors and for forming residual autologous growth factor compositions |
US8048083B2 (en) | 2004-11-05 | 2011-11-01 | Dfine, Inc. | Bone treatment systems and methods |
US20060264965A1 (en) * | 2004-11-05 | 2006-11-23 | Shadduck John H | Bone treatment systems and methods |
US8932300B2 (en) | 2004-11-05 | 2015-01-13 | Dfine, Inc. | Bone treatment systems and methods |
US20090030451A1 (en) * | 2005-02-09 | 2009-01-29 | Hadba Ahmad R | Synthetic Sealants |
US9707252B2 (en) | 2005-02-09 | 2017-07-18 | Covidien Lp | Synthetic sealants |
US20060178743A1 (en) * | 2005-02-10 | 2006-08-10 | Spine Wave, Inc. | Synovial fluid barrier |
US7825083B2 (en) | 2005-02-10 | 2010-11-02 | Spine Wave, Inc. | Synovial fluid barrier |
US20060271089A1 (en) * | 2005-04-11 | 2006-11-30 | Cierra, Inc. | Methods and apparatus to achieve a closure of a layered tissue defect |
US8109274B2 (en) | 2005-04-11 | 2012-02-07 | Terumo Kabushiki Kaisha | Methods and electrode apparatus to achieve a closure of a layered tissue defect |
US20060271040A1 (en) * | 2005-04-11 | 2006-11-30 | Cierra, Inc. | Methods and electrode apparatus to achieve a closure of a layered tissue defect |
US10342635B2 (en) | 2005-04-20 | 2019-07-09 | Bard Peripheral Vascular, Inc. | Marking device with retractable cannula |
US20090012525A1 (en) * | 2005-09-01 | 2009-01-08 | Eric Buehlmann | Devices and systems for delivering bone fill material |
US8133336B2 (en) | 2006-02-03 | 2012-03-13 | Tissuemed Limited | Tissue-adhesive materials |
US20070233249A1 (en) * | 2006-02-07 | 2007-10-04 | Shadduck John H | Methods for treating bone |
US20070233250A1 (en) * | 2006-02-07 | 2007-10-04 | Shadduck John H | Systems for treating bone |
US20100028309A1 (en) * | 2006-05-31 | 2010-02-04 | Baxter International Inc. | Method for directed cell in-growth and controlled tissue regeneration in spinal surgery |
US8703122B2 (en) | 2006-05-31 | 2014-04-22 | Baxter International Inc. | Method for directed cell in-growth and controlled tissue regeneration in spinal surgery |
US20080026032A1 (en) * | 2006-07-27 | 2008-01-31 | Zubery Yuval | Composite implants for promoting bone regeneration and augmentation and methods for their preparation and use |
EP3466454A1 (en) | 2006-08-02 | 2019-04-10 | Baxter International Inc | Rapidly acting dry sealant and methods for use and manufacture |
US20080187591A1 (en) * | 2006-08-02 | 2008-08-07 | Baxter International, Inc. | Rapidly acting dry sealant and methods for use and manufacture |
US8962025B2 (en) | 2006-08-02 | 2015-02-24 | Baxter International Inc. | Rapidly acting dry sealant and methods for use and manufacture |
EP2468310A1 (en) | 2006-08-02 | 2012-06-27 | Baxter International Inc | Rapidly acting dry sealant and methods for use and manufacture |
EP3909619A1 (en) | 2006-08-02 | 2021-11-17 | Baxter International Inc | Rapidly acting dry sealant and methods for use and manufacture |
US9114172B2 (en) | 2006-08-02 | 2015-08-25 | Baxter International Inc. | Rapidly acting dry sealant and methods for use and manufacture |
US20080140069A1 (en) * | 2006-12-07 | 2008-06-12 | Cierra, Inc. | Multi-electrode apparatus for tissue welding and ablation |
US20080188858A1 (en) * | 2007-02-05 | 2008-08-07 | Robert Luzzi | Bone treatment systems and methods |
US20090227981A1 (en) * | 2007-03-05 | 2009-09-10 | Bennett Steven L | Low-Swelling Biocompatible Hydrogels |
US20090227689A1 (en) * | 2007-03-05 | 2009-09-10 | Bennett Steven L | Low-Swelling Biocompatible Hydrogels |
US20080267902A1 (en) * | 2007-04-27 | 2008-10-30 | Hillary Enyart | Blood products with binding agent |
US8092837B2 (en) | 2007-04-27 | 2012-01-10 | Biomet Manufacturing Corp | Fibrin based glue with functionalized hydrophilic polymer protein binding agent |
US20100203033A1 (en) * | 2007-07-02 | 2010-08-12 | Israel Nur | Kits, formulations and solutions having enzymatically- permissive amounts of visualization agents and uses thereof |
EP2508211A1 (en) | 2007-07-02 | 2012-10-10 | Omrix Biopharmaceuticals Ltd. | Solutions having enzymatically-permissive amounts of visualization agents and uses thereof. |
US9775906B2 (en) | 2007-07-09 | 2017-10-03 | Incept Llc | Hydrogel polymeric compositions and methods |
US11324828B2 (en) | 2007-07-09 | 2022-05-10 | Incept, Llc | Hydrogel polymeric compositions and methods |
US10251954B2 (en) | 2007-07-09 | 2019-04-09 | Incept, Llc | Hydrogel polymeric compositions and methods |
US20110027335A1 (en) * | 2007-08-10 | 2011-02-03 | Tissuemed Limited | Coated medical devices |
US20090092651A1 (en) * | 2007-10-05 | 2009-04-09 | Bhavin Shah | Absorbable adhesives and their formulation for use in medical applications |
US10500309B2 (en) | 2007-10-05 | 2019-12-10 | Cook Biotech Incorporated | Absorbable adhesives and their formulation for use in medical applications |
US8790698B2 (en) | 2007-10-30 | 2014-07-29 | Baxter International Inc. | Use of a regenerative biofunctional collagen biomatrix for treating visceral or parietal defects |
US9789221B2 (en) | 2007-12-03 | 2017-10-17 | Mallinckrodt Pharma Ip Trading D.A.C. | Biocompatible phase invertible proteinaceous compositions and methods for making and using the same |
US10675378B2 (en) | 2007-12-03 | 2020-06-09 | Baxter International Inc. | Biocompatible phase invertible proteinaceous compositions and methods for making and using the same |
WO2009073668A1 (en) | 2007-12-03 | 2009-06-11 | Tenaxis Medical, Inc. | Biocompatible phase invertible proteinaceous compositions |
US20090143500A1 (en) * | 2007-12-03 | 2009-06-04 | Ronald Dieck | Biocompatible phase invertible proteinaceous compositions and methods for making and using the same |
US8586671B2 (en) | 2007-12-03 | 2013-11-19 | Tenaxis Medical, Inc. | Biocompatible phase invertible proteinaceous compositions and methods for making and using the same |
US11583611B2 (en) | 2007-12-03 | 2023-02-21 | Baxter International Inc. | Biocompatible phase invertible proteinaceous compositions and methods for making and using the same |
US10279073B2 (en) | 2007-12-03 | 2019-05-07 | Baxter International Inc. | Biocompatible phase invertible proteinaceous compositions and methods for making and using the same |
US8198363B2 (en) | 2007-12-03 | 2012-06-12 | Tenaxis Medical, Inc. | Biocompatible phase invertible proteinaceous compositions and methods for making and using the same |
US8961541B2 (en) | 2007-12-03 | 2015-02-24 | Cardio Vascular Technologies Inc. | Vascular closure devices, systems, and methods of use |
US20090155197A1 (en) * | 2007-12-14 | 2009-06-18 | Smith Molly K | Goniochromic indicator for skin sealant |
US9445854B2 (en) | 2008-02-01 | 2016-09-20 | Dfine, Inc. | Bone treatment systems and methods |
US20100016467A1 (en) * | 2008-02-01 | 2010-01-21 | Dfine, Inc. | Bone treatment systems and methods |
US10080817B2 (en) | 2008-02-01 | 2018-09-25 | Dfine, Inc. | Bone treatment systems and methods |
US8487021B2 (en) | 2008-02-01 | 2013-07-16 | Dfine, Inc. | Bone treatment systems and methods |
US20090247664A1 (en) * | 2008-02-01 | 2009-10-01 | Dfine, Inc. | Bone treatment systems and methods |
US9216195B2 (en) | 2008-02-28 | 2015-12-22 | Dfine, Inc. | Bone treatment systems and methods |
US9821085B2 (en) | 2008-02-28 | 2017-11-21 | Dfine, Inc. | Bone treatment systems and methods |
US9533069B2 (en) | 2008-02-29 | 2017-01-03 | Ferrosan Medical Devices A/S | Device for promotion of hemostasis and/or wound healing |
US10166258B2 (en) | 2008-09-16 | 2019-01-01 | Mayo Foundation For Medical Education And Research | Compositions containing platelet contents |
US10925901B2 (en) | 2008-09-16 | 2021-02-23 | Mayo Foundation For Medical Education And Research | Compositions containing platelet contents |
US20110171731A1 (en) * | 2008-09-16 | 2011-07-14 | Dietz Allan B | Compositions containing platelet contents |
US11779431B2 (en) | 2008-12-30 | 2023-10-10 | C. R. Bard, Inc. | Marker delivery device for tissue marker placement |
US8563027B2 (en) | 2009-02-12 | 2013-10-22 | Incept, Llc | Drug delivery through hydrogel plugs |
US20100209478A1 (en) * | 2009-02-12 | 2010-08-19 | Sawhney Amarpreet S | Drug delivery through hydrogel plugs |
US8409606B2 (en) | 2009-02-12 | 2013-04-02 | Incept, Llc | Drug delivery through hydrogel plugs |
US9440000B2 (en) | 2009-04-17 | 2016-09-13 | Mallinckrodt Pharma Ip Trading D.A.C. | Biocompatible phase invertible proteinaceous compositions and methods for making and using the same |
US10328176B2 (en) | 2009-04-17 | 2019-06-25 | Baxter International Inc. | Biocompatible phase invertible proteinaceous compositions and methods for making and using the same |
US11478569B2 (en) | 2009-04-17 | 2022-10-25 | Baxter International Inc. | Biocompatible phase invertible proteinaceous compositions and methods for making and using the same |
US20110093006A1 (en) * | 2009-04-17 | 2011-04-21 | Tenaxis Medical, Inc. | Biocompatible phase invertible proteinaceous compositions and methods for making and using the same |
US9155815B2 (en) | 2009-04-17 | 2015-10-13 | Tenaxis Medical, Inc. | Biocompatible phase invertible proteinaceous compositions and methods for making and using the same |
WO2010121051A1 (en) | 2009-04-17 | 2010-10-21 | Tenaxis Medical, Inc. | Biocompatible phase invertible proteinaceous compositions and methods for making and using the same |
US10722610B2 (en) | 2009-04-17 | 2020-07-28 | Baxter International Inc. | Biocompatible phase invertible proteinaceous compositions and methods for making and using the same |
US10881759B2 (en) | 2009-04-27 | 2021-01-05 | Medibeacon Inc. | Tissue sealant compositions, vascular closure devices, and uses thereof |
US9433700B2 (en) | 2009-04-27 | 2016-09-06 | Medibeacon Inc. | Tissue sealant compositions, vascular closure devices, and uses thereof |
US10960104B2 (en) | 2009-04-27 | 2021-03-30 | Medibeacon Inc. | Tissue sealant compositions, vascular closure devices, and uses thereof |
US10967096B2 (en) | 2009-04-27 | 2021-04-06 | Medibeacon Inc. | Tissue sealant compositions, vascular closure devices, and uses thereof |
US9045600B2 (en) | 2009-05-13 | 2015-06-02 | Keraplast Technologies, Ltd. | Biopolymer materials |
US9039783B2 (en) | 2009-05-18 | 2015-05-26 | Baxter International, Inc. | Method for the improvement of mesh implant biocompatibility |
US20100292717A1 (en) * | 2009-05-18 | 2010-11-18 | Baxter International Inc. | Method for the improvement of mesh implant biocompatibility |
US9993298B2 (en) | 2009-05-18 | 2018-06-12 | Baxter International Inc. | Method for the improvement of mesh implant biocompatibility |
US20100318048A1 (en) * | 2009-06-16 | 2010-12-16 | Baxter International Inc. | Hemostatic sponge |
US9162006B2 (en) | 2009-06-16 | 2015-10-20 | Baxter International Inc. | Hemostatic sponge |
US9517287B2 (en) | 2009-12-16 | 2016-12-13 | Baxter International, Inc. | Hemostatic sponge |
US11071804B2 (en) | 2009-12-16 | 2021-07-27 | Baxter International Inc. | Hemostatic sponge |
US9872934B2 (en) | 2009-12-16 | 2018-01-23 | Baxter International Inc. | Hemostatic sponge |
US20110202026A1 (en) * | 2009-12-16 | 2011-08-18 | Baxter International Inc. | Hemostatic sponge |
US8771258B2 (en) | 2009-12-16 | 2014-07-08 | Baxter International Inc. | Hemostatic sponge |
US10070915B2 (en) | 2010-01-26 | 2018-09-11 | Covidien Lp | Hernia repair system |
US8617157B2 (en) | 2010-01-26 | 2013-12-31 | Covidien Lp | Hernia repair system |
US20110184407A1 (en) * | 2010-01-26 | 2011-07-28 | Tyco Healthcare Group Lp | Hernia Repair System |
US11478566B2 (en) | 2010-04-07 | 2022-10-25 | Baxter International Inc. | Hemostatic sponge |
US8703170B2 (en) | 2010-04-07 | 2014-04-22 | Baxter International Inc. | Hemostatic sponge |
US9375505B2 (en) | 2010-04-07 | 2016-06-28 | Baxter International Inc. | Hemostatic sponge |
US10441674B2 (en) | 2010-04-07 | 2019-10-15 | Baxter International Inc. | Hemostatic sponge |
US8940335B2 (en) | 2010-06-01 | 2015-01-27 | Baxter International Inc. | Process for making dry and stable hemostatic compositions |
US10994045B2 (en) | 2010-06-01 | 2021-05-04 | Baxter International Inc. | Process for making dry and stable hemostatic compositions |
US9084728B2 (en) | 2010-06-01 | 2015-07-21 | Baxter International Inc. | Process for making dry and stable hemostatic compositions |
US10245348B2 (en) | 2010-06-01 | 2019-04-02 | Baxter International Inc. | Process for making dry and stable hemostatic compositions |
US9408945B2 (en) | 2010-06-01 | 2016-08-09 | Baxter International Inc. | Process for making dry and stable hemostatic compositions |
US10849652B2 (en) | 2010-10-05 | 2020-12-01 | Emory University | Devices, systems, and methods for improving access to cardiac and vascular chambers |
WO2012135808A3 (en) * | 2011-04-01 | 2012-12-27 | The Johns Hopkins University | Intraoperative and blood-derived adhesives |
US11745026B2 (en) | 2011-04-01 | 2023-09-05 | The Bioregentech Institute, Inc. | Laser assisted wound healing protocol and system |
US11684797B2 (en) | 2011-04-01 | 2023-06-27 | The Bioregentech Institute, Inc. | Laser assisted wound healing protocol and system |
US11730760B2 (en) | 2011-04-01 | 2023-08-22 | The Bioregentech Institute, Inc. | Laser assisted wound healing protocol and system |
US11389663B2 (en) * | 2011-04-01 | 2022-07-19 | Bioregentech, Inc. | Laser assisted wound healing protocol and system |
WO2012135808A2 (en) * | 2011-04-01 | 2012-10-04 | The Johns Hopkins University | Intraoperative and blood-derived adhesives |
US10322170B2 (en) | 2011-10-11 | 2019-06-18 | Baxter International Inc. | Hemostatic compositions |
US9821025B2 (en) | 2011-10-11 | 2017-11-21 | Baxter International Inc. | Hemostatic compositions |
US9833541B2 (en) | 2011-10-27 | 2017-12-05 | Baxter International Inc. | Hemostatic compositions |
US9956311B2 (en) | 2012-02-03 | 2018-05-01 | Xcede Technologies, Inc. | Tissue patch |
US8999376B2 (en) | 2012-02-03 | 2015-04-07 | Xcede Technologies, Inc. | Tissue patch |
US9352067B2 (en) | 2012-02-03 | 2016-05-31 | Xcede Technologies, Inc. | Tissue patch |
US9821114B2 (en) | 2012-02-07 | 2017-11-21 | Global Bio Therapeutics, Inc. | Compartmentalized method of nucleic acid delivery and compositions and uses thereof |
EP3970734A2 (en) | 2012-02-07 | 2022-03-23 | Global Bio Therapeutics, Inc. | Compartmentalized method of nucleic acid delivery and compositions and uses thereof |
WO2013119880A1 (en) | 2012-02-07 | 2013-08-15 | Global Bio Therapeutics Usa, Inc. | Compartmentalized method of nucleic acid delivery and compositions and uses thereof |
US11109849B2 (en) | 2012-03-06 | 2021-09-07 | Ferrosan Medical Devices A/S | Pressurized container containing haemostatic paste |
US10213373B2 (en) | 2012-04-20 | 2019-02-26 | Klox Technologies, Inc. | Chromophore combinations for biophotonic uses |
US11331257B2 (en) | 2012-04-20 | 2022-05-17 | Klox Technologies Inc. | Biophotonic compositions and methods for providing biophotonic treatment |
US11116841B2 (en) | 2012-04-20 | 2021-09-14 | Klox Technologies Inc. | Biophotonic compositions, kits and methods |
US10376455B2 (en) * | 2012-04-20 | 2019-08-13 | Klox Technologies Inc. | Biophotonic compositions and methods for providing biophotonic treatment |
US11723854B2 (en) | 2012-04-20 | 2023-08-15 | Fle International S.R.L. | Biophotonic compositions and methods for providing biophotonic treatment |
US20130281913A1 (en) * | 2012-04-20 | 2013-10-24 | Klox Technologies Inc. | Biophotonic compositions and methods for providing biophotonic treatment |
US9265858B2 (en) | 2012-06-12 | 2016-02-23 | Ferrosan Medical Devices A/S | Dry haemostatic composition |
US9999703B2 (en) | 2012-06-12 | 2018-06-19 | Ferrosan Medical Devices A/S | Dry haemostatic composition |
US10799611B2 (en) | 2012-06-12 | 2020-10-13 | Ferrosan Medical Devices A/S | Dry haemostatic composition |
US10549112B2 (en) | 2012-07-20 | 2020-02-04 | The General Hospital Corporation | Apparatus for tissue irradiation and methods and kits utilizing the same |
US10478284B2 (en) | 2012-07-20 | 2019-11-19 | The General Hospital Corporation | Methods for tissue passivation |
US10292381B2 (en) | 2012-07-20 | 2019-05-21 | The General Hospital Corporation | Vessel treatment systems, methods, and kits |
US11324823B2 (en) | 2013-03-14 | 2022-05-10 | Klox Technologies Inc. | Biophotonic materials and uses thereof |
US10130706B2 (en) | 2013-03-14 | 2018-11-20 | Klox Technologies Inc. | Biophotonic materials and uses thereof |
US9724078B2 (en) | 2013-06-21 | 2017-08-08 | Ferrosan Medical Devices A/S | Vacuum expanded dry composition and syringe for retaining same |
US10595837B2 (en) | 2013-06-21 | 2020-03-24 | Ferrosan Medical Devices A/S | Vacuum expanded dry composition and syringe for retaining same |
US10881736B2 (en) | 2013-07-03 | 2021-01-05 | Klox Technologies Inc. | Biophotonic compositions comprising a chromophore and a gelling agent for treating wounds |
US11350625B2 (en) | 2013-07-18 | 2022-06-07 | The General Hospital Corporation | Vessel treatment systems, methods, and kits |
US11364032B2 (en) | 2013-08-08 | 2022-06-21 | Global Bio Therapeutics, Inc. | Clamp device for minimally invasive procedures and uses thereof |
US9888991B2 (en) * | 2013-12-09 | 2018-02-13 | Boston Scientific Scimed, Inc. | Compositions, devices, kits and methods for attaching surgical meshes to tissue |
US20150157439A1 (en) * | 2013-12-09 | 2015-06-11 | Boston Scientific Scimed, Inc. | Compositions, devices, kits and methods for attaching surgical meshes to tissue |
WO2015089020A1 (en) * | 2013-12-09 | 2015-06-18 | Boston Scientific Scimed, Inc. | Compositions, devices, kits and methods for attaching surgical meshes to tissue |
US10111980B2 (en) | 2013-12-11 | 2018-10-30 | Ferrosan Medical Devices A/S | Dry composition comprising an extrusion enhancer |
US11103616B2 (en) | 2013-12-11 | 2021-08-31 | Ferrosan Medical Devices A/S | Dry composition comprising an extrusion enhancer |
US9655707B2 (en) | 2014-02-06 | 2017-05-23 | Boston Scientific Scimed, Inc. | Methods, compositions, devices and kits for attaching surgical slings to tissue |
US10207029B2 (en) | 2014-04-01 | 2019-02-19 | Klox Technologies Inc. | Tissue filler compositions and methods of use |
US10772990B2 (en) | 2014-04-01 | 2020-09-15 | Klox Technologies Inc. | Tissue filler compositions and methods of use |
US11891620B2 (en) | 2014-05-16 | 2024-02-06 | Mayo Foundation For Medical Education And Research | Cell culture media compositions for primary cells |
US11046818B2 (en) | 2014-10-13 | 2021-06-29 | Ferrosan Medical Devices A/S | Dry composition for use in haemostasis and wound healing |
US11421349B2 (en) | 2014-10-31 | 2022-08-23 | Klox Technologies Inc. | Photoactivatable fibers and fabric media |
US10653837B2 (en) | 2014-12-24 | 2020-05-19 | Ferrosan Medical Devices A/S | Syringe for retaining and mixing first and second substances |
US11369591B2 (en) | 2015-05-12 | 2022-06-28 | Incept, Llc | Drug delivery from hydrogels |
US10918796B2 (en) | 2015-07-03 | 2021-02-16 | Ferrosan Medical Devices A/S | Syringe for mixing two components and for retaining a vacuum in a storage condition |
US9833538B2 (en) | 2015-08-07 | 2017-12-05 | Xcede Technologies, Inc. | Adhesive compositions and related methods |
US10722611B2 (en) | 2015-08-07 | 2020-07-28 | Xcede Technologies, Inc. | Adhesive compositions and related methods |
US10588998B2 (en) | 2015-08-07 | 2020-03-17 | Xcede Technologies, Inc. | Adhesive compositions and related methods |
US9540548B1 (en) | 2015-08-07 | 2017-01-10 | Xcede Technologies, Inc. | Adhesive compositions and related methods |
US11654293B2 (en) * | 2016-11-10 | 2023-05-23 | The Bioregentech Institute, Inc. | Laser assisted wound healing protocol and system |
WO2019135237A1 (en) * | 2018-01-04 | 2019-07-11 | Ramot At Tel-Aviv University Ltd. | Scaffold for tissue welding |
US11801324B2 (en) | 2018-05-09 | 2023-10-31 | Ferrosan Medical Devices A/S | Method for preparing a haemostatic composition |
WO2019231763A1 (en) | 2018-05-27 | 2019-12-05 | Christos Angeletakis | Tissue adhesives and sealants using naturally derived aldehydes |
US11739166B2 (en) | 2020-07-02 | 2023-08-29 | Davol Inc. | Reactive polysaccharide-based hemostatic agent |
TWI814462B (en) * | 2021-08-24 | 2023-09-01 | 國立臺灣大學 | Manufacturing method of hemostatic material and hemostatic material prepared thereby |
CN113876997A (en) * | 2021-09-27 | 2022-01-04 | 广东省科学院健康医学研究所 | Albumin composite adhesive and preparation method thereof |
Also Published As
Publication number | Publication date |
---|---|
ES2137930T3 (en) | 2000-01-01 |
EP0542880A4 (en) | 1993-07-28 |
WO1992002238A1 (en) | 1992-02-20 |
DE69131556T2 (en) | 2000-07-20 |
ATE183656T1 (en) | 1999-09-15 |
JPH06507376A (en) | 1994-08-25 |
AU8497991A (en) | 1992-03-02 |
CA2087957A1 (en) | 1992-01-28 |
EP0542880B1 (en) | 1999-08-25 |
CA2087957C (en) | 2004-07-20 |
DE69131556D1 (en) | 1999-09-30 |
EP0542880A1 (en) | 1993-05-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5292362A (en) | Tissue bonding and sealing composition and method of using the same | |
US5209776A (en) | Tissue bonding and sealing composition and method of using the same | |
JP3735677B2 (en) | Surgical adhesive composition based on non-crosslinked collagen modified by oxidative degradation | |
AU646406B2 (en) | Laser tissue welding with dye enhanced solders | |
US5824015A (en) | Method for welding biological tissue | |
US6773699B1 (en) | Light energized tissue adhesive conformal patch | |
US6939364B1 (en) | Composite tissue adhesive | |
US20030032143A1 (en) | Collagen type I and type III compositions for use as an adhesive and sealant | |
US20020015724A1 (en) | Collagen type i and type iii hemostatic compositions for use as a vascular sealant and wound dressing | |
AU5671899A (en) | Collagen type i and type iii hemostatic compositions for use as a vascular sealant and wound dressing | |
CN105521521A (en) | Lung sealing medical gel, and preparing method and application thereof | |
JP5671209B2 (en) | Tissue binding and / or sealing by photoactivated cross-linking of matrix proteins | |
US6780840B1 (en) | Method for making a light energized tissue adhesive | |
US6875427B1 (en) | Light energized tissue adhesive | |
JP2001511431A (en) | Type I and type III collagen adhesive compositions | |
Self et al. | Limited thrombogenicity of low temperature, laser‐welded vascular anastomoses | |
Cespanyi et al. | Preliminary report: a new technique of enterotomy closure using Nd: YAG laser welding compared to suture repair | |
WO1992013547A1 (en) | Drug delivery composition and method of using the same | |
USRE43134E1 (en) | Biocompatible denatured albumin lamina | |
Bass et al. | Soldering is a superior alternative to fibrin sealant | |
Khadem et al. | Healing of perforating rat corneal incisions closed with photodynamic laser‐activated tissue glue | |
NOWYGROD et al. | LS BASS, SK LIBUTTI, ML KAYTON | |
Farruggia | Alan Prahl, Portland, OR (US) | |
Vo-Dinh | Laser Tissue Welding | |
WO2001026624A1 (en) | Biocompatible albumin lamina and method |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF YOR Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNOR:EATON, ALEXANDER M.;REEL/FRAME:006414/0706 Effective date: 19921210 Owner name: TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF YOR Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNOR:LIBUTTI, STEVEN K.;REEL/FRAME:006419/0096 Effective date: 19930114 Owner name: TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF YOR Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNOR:BASS, LAWRENCE S.;REEL/FRAME:006423/0425 Effective date: 19921224 |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
FPAY | Fee payment |
Year of fee payment: 4 |
|
REMI | Maintenance fee reminder mailed | ||
FPAY | Fee payment |
Year of fee payment: 8 |
|
SULP | Surcharge for late payment |
Year of fee payment: 7 |
|
FPAY | Fee payment |
Year of fee payment: 12 |